On the surface it looks bad.

• FY2025 revenue fell 9.2 percent to S$177.4 million,

• Net profit attributable to shareholders dropped 43 percent to S$5.8 million (S$6.1 million including non-controlling interests, the figure on the company’s highlights page [4]),

• Earnings per share went from 3.30 cents to 1.89, and

• Vietnam, until recently the second-largest market, collapsed 30.8 percent.

At S$0.35 [1] the market has filed Hyphens under “small-cap distributor in decline.”

Now the other line. The gross profit did not go down; rather, it increased to a new high of S$72.2 million from a new high margin of 40.7 percent, while the operating cash flow increased sharply to S$18.7 million, from practically nothing. Businesses in decline do not set new highs in gross profits and cash flow during the very year that revenues peak and decline. The problem is not whether FY2025 was bad. It was. The question is whether the bad year upgraded the earnings base.

Begin with understanding what Hyphens is – three businesses:

1. It in-licenses specialty drugs and aesthetics products and distributes them in more than five Southeast Asian countries;

2. It owns a growing set of brands like Ceradan and Ocean Health that carry a fatter margin; and

3. It operates docmedtech.com, a money-losing digital and wholesale business unit.

The point to remember here is that during the FY2025 period the company moved two products into the category of owned-brands and hence the reported figures showing 33% growth for that category are misleading along with an exaggerated 18% drop in the pharmaceuticals category.

Split the year in half, and the story becomes more compelling. Gross margin ended FY2025 at 42.0% in the second half of the year, versus around 39% in the first and 36% a year ago, the best in six years. The startling profit decline has been almost entirely contained within the first half of the year, when net profit plunged 66% compared to just 17% in the second half of the year. The first half decline is not attributable to a trading issue. While gross profit increased in the first half, this is because of problems further down the profit line due to Sterimar inventory write downs and foreign exchange losses, not loss of business.

The revenue bars are lumpy for reasons outside the thesis: the 2022 step up is the Novem acquisition consolidating for its first full year, and the 1H2024 peak was a post-disruption restocking bulge that then unwound. Gross profit, the steadier navy line, is the one that matters.

Let’s also be fair to the other side. The one thing that has mostly caused the decline in the revenue was Vietnam. This seems more like a regulatory problem caused by the obligatory reduction and not an optional one. According to management, the cause of the loss of the business in that country is due to them imposing stringent regulations on the pharmacies and the supply chain, which is evident through the new pharmacy laws in Vietnam and an inspection that will be carried out in 2025 [6].

The forward case rests on the owned brands. Hyphens in January 2026 did something that a pure distributor never does: it licensed its proprietary formula of Cerapro to a dermatology company from Switzerland for an up-front payment and royalties [2], demonstrating that owned technology has value. Medical aesthetics, via the Ardence acquisition, is the second pillar; though it remains small, it relies heavily on its founder’s presence. This is the best part of the portfolio, which explains why the gross margin can continue rising.

Now the number. Add back the genuine one-offs, chiefly a S$2.0 million Sterimar write-down plus smaller Vietnam and Ardence charges, about S$2.9 million before tax in total or roughly S$2.3 million after, and normalised earnings are about S$8.1 million against the S$5.8 million reported

On this basis, our FY2025 underlying earnings is down 15-20%, not 43%.

Given the currency headwind of S$2.8m needs to stay in the base as much as anything else (we’re assuming a currency effect annually whenever you do your buying in dollars and your selling in all sorts of other currencies around the region), a figure a bit above S$10.3m arises, which we will take to not be our base given that this is rather steep of a base to run on.

Yet, not all good business is a good stock. Hyphens, trading at 18.5x forward on S$0.35, sports P/E around the low teens to mid teens on our adjusted- earnings (and cash), while the market’s forward 8x P/E has it factoring a recovery of profits to S$13m-a level we think is too aggressive even on future predictions [2]. One free option sits on top: in 2022 a listed strategic, Metro Holdings, paid real cash for a slice of the digital-and-wholesale arm at a level the market now ignores [3], though the mark is stale and we credit it with nothing.

Three catches keep this honest.

To start, liquidity. Only 23.7 per cent of the stock, around S$25 million worth, is publicly held as two owners control the rest – more than two-thirds. This means no institution can add to a stake, or get rid of one, without affecting the market, and for long, so why shouldn’t the discount stay put and its causes perpetuate its presence.

Then, history. With S$10 million in net profit notched only twice in eight years as a listed company, the adjusted normalized base looks more like the midpoint of what it tends to deliver rather than a support floor.

Last, signals. Buying from CEO [5] deserves to be flagged, though against his existing control stake, it is trivial, and in a cash loaded, poorly performing public, it could mean either an inexpensive take private bid or re-rating. And don’t give the executive management’s promises much heed, as last year, for instance, it assured stakeholders the Vietnamese regulatory system would see no real shifts ahead - this was weeks before its collapse caused, it later insisted, by policy changes.

And what do you do with it? Not much, for a while. This is a watch-one-number scenario, and that one number is gross profit dollars. It is constructed to be a small position and watchlist candidate, not an investment; the float is just too thin to make a difference, the 4.3% dividend pays you to wait, and waiting may take a while.

The test is clean and close.

• The next results come out in mid-August, covering the first half of 2026. One number tells you most of what you need: is gross profit still growing, above the S$35.3 million the group made in the first half of 2025? But gross profit alone is not the answer. It only helps you if it reaches the bottom line, instead of being spent on the marketing needed to sell those brands. And that risk is real, not theoretical. In the second half of 2025 the owned-brands arm grew its sales but earned less, because growing it cost more than it brought in.

• So here is the good outcome: if gross profit keeps rising and this time reaches profit, then the market was ignoring a business that was quietly getting better, and that is exactly why you could buy it cheap.

• And the bad outcome: if the marketing eats the gain, then FY2025 just made the company smaller at a nicer margin, no richer, and the low share price was right all along.

Watch that line, all the way to the bottom one.

Data integrity notes

All figures are from Hyphens Pharma’s SGX filings, except share price and market data, which are from Yahoo Finance at the 23 July 2026 close [1]. Net profit is the attributable figure, S$5.8 million; the S$6.1 million on the company’s highlights page is the total before the 3.5 percent attributable to non-controlling interests [4]. Two caveats matter: the FY2025 segment reclassification means the 33 percent Proprietary Brands growth is not clean like-for-like, and the first-half figures we use are derived from full-year figures less the company’s reported second half. A basic governance and accounting red-flag screen did not show obvious issues, with goodwill tested without impairment, an unqualified audit, and operating cash flow above reported net profit.

References

[1] Hyphens Pharma International (1J5.SI), share price and market data via Yahoo Finance, at the 23 July 2026 close (S$0.35). https://finance.yahoo.com/quote/1J5.SI

[2] “Hyphens Pharma out-licences Cerapro MED Skin Barrier Cream for six European countries,” Hyphens Pharma media release, 5 January 2026. https://www.hyphensgroup.com/media-release-hyphens-pharma-out-licences-cerapro-med-skin-barrier-cream-for-six-european-countries/

[3] “Metro Holdings takes 10% stake in Hyphens Pharma subsidiary DocMed at $60 mil valuation,” The Edge Singapore, 27 May 2022. https://www.theedgesingapore.com/news/ma/metro-holdings-takes-10-stake-hyphens-pharma-subsidiary-docmed-60-mil-valuation

[4] Hyphens Pharma International, Financial Highlights. https://www.hyphensgroup.com/investor-relations/financial-highlights/

[5] “Directors increase stakes in Aspial Lifestyle, Raffles Medical Group, Centurion, among others,” The Business Times, 24 May 2026. https://www.businesstimes.com.sg/companies-markets/directors-increase-stakes-aspial-lifestyle-raffles-medical-group-centurion-among-others

Primary filings (SGX disclosures, no inline citation): Hyphens Pharma International Limited, FY2025 full-year results (24 February 2026); FY2020 to FY2024 results and half-year results; Annual Report 2025; and Responses to Substantial and Relevant Questions from Shareholders for the 2026 AGM.

Disclaimer and holdings

This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore and this content is exempt under Regulation 34 of the Financial Advisers Regulations as a generally available publication. Consult a licensed adviser before investing. Past performance is not indicative of future results. The author holds no position in the securities discussed.

The mirage

In January 2026, Jollibee Foods Corporation said it would separate its international business from its Philippine operations and list the overseas arm on a United States exchange, handing existing shareholders stock in the new company. It was something no Philippine consumer company had attempted at this scale, and local brokers greeted it as a way to unlock the value of a global restaurant group the Manila market had never fully credited. Investors liked it at once, and the shares rose around 16 percent [2]. Two-thirds of Jollibee's more than 10,000 stores sit outside the Philippines, and the pitch was simple: put that fast-growing global business in front of American investors who pay up for restaurant growth, keep the steady Philippine cash machine at home, and the sum of the parts is worth more than the blended company trading in Manila. The logic was easy to follow, and for a few days the market bought all of it.

Six months later the enthusiasm had cooled. At its June annual meeting the company no longer described a spin-off and a 2027 US listing but an “ongoing strategic review” with “multiple pathways to unlock value over time,” one that would proceed “regardless of the outcome,” and the venue had drifted from New York toward Hong Kong [3]. The company’s annual-meeting messaging placed the separation inside a broader strategic review rather than repeating January’s firm transaction language. The shares gave back the excitement and now trade in the 140s, about a third below their level a year ago.

Most of the debate since has been about whether the spin happens. That is the wrong question. The more important one, which almost nobody asks, is whether it would deliver the thing it is premised on: a Wall Street re-rating of the international arm. And there is evidence to test it, because the market has already run several versions of the experiment.

The spin-off can crystallise value, but the listing alone cannot durably multiply it. The reason is simple: the closest available US-listed precedents, each Chinese or Chinese-origin, have not sustained US growth multiples. Chagee IPO’d on Nasdaq in 2025 at roughly 2.5 to 3 times sales on an enterprise basis and, as its growth cooled, fell to about 0.7; Yum China, spun off and NYSE-listed, sits near 1.3.

That matters because the bull case depends on a venue re-rating. Jollibee’s international arm may be valuable, but its value is already explainable on Asian marks. The mirage is not the business; it is the idea that New York changes the multiple. What follows builds that case from the filings up: what Jollibee is, where its profit sits, what it has bought, and then the test itself.

What Jollibee really is

Built from a single ice cream parlour the Tan family opened in 1975, Jollibee is now one of Asia’s largest restaurant operators, with more than 10,400 stores across 33 countries and around 20 brands. When customers at that ice cream parlour kept asking for hot meals, the founders switched the menu to burgers and fried chicken and incorporated the business as Jollibee in 1978. The defining moment came in 1981, when McDonald’s entered the Philippines and, against every expectation, failed to dislodge the local upstart: Jollibee had tuned its food to a Filipino palate, sweeter burgers and saltier fried chicken, that global chains never quite matched. To this day the Philippines is one of the very few markets on earth where the home-grown chain outsells McDonald’s on its own ground, and Brand Finance ranks Jollibee the most valuable restaurant brand in Southeast Asia [4]. That victory taught the company two lessons that still shape it: that local taste and habit beat global scale, which is why the domestic business is so hard to dislodge; and that the formula does not automatically travel, because the home-turf advantage is exactly what it lacks everywhere else.

Underneath the brands sit three businesses. The first is operating restaurants, some company-owned, most franchised, and the distinction drives the economics. A franchised store sends Jollibee a royalty with almost no incremental cost or capital; a company-owned store carries the full weight of rent, staff and fit-out. Jollibee’s mature domestic brands lean heavily franchised, which is why the home business throws off cash, while several overseas businesses are more company-operated, which is one reason they consume it. The flagship makes the split visible: of the 1,279 Jollibee-branded stores in the Philippines at the end of 2024, about two-thirds were franchised; of the 480 abroad, three-quarters were company-owned. Same brand, inverted model.

The second business is the commissary and supply chain, a network of central kitchens and distribution centres that manufactures the standardised sauces, marinades and frozen components which make a Chickenjoy in Davao taste like one in Manila. It is unglamorous, and it is a real moat: it enforces consistency, captures manufacturing margin a pure franchisor would hand to suppliers, and cannot be cheaply copied. A competitor can clone a recipe; it cannot clone a nationwide commissary built over four decades.

The third business, increasingly central, is capital allocation, which is to say buying restaurant companies. The domestic portfolio was assembled partly by acquisition; the international arm almost wholly so. This makes Jollibee as much an acquirer and operator of brands as a single chain, and it is the fact that most shapes how the overseas business should be valued. Management has spoken for years of becoming one of the largest restaurant companies in the world, so the spin-off is the logical endpoint of a decades-long ambition rather than a sudden idea, which is part of why the company is reluctant to abandon it even as the mechanics turn out to be hard. Two familiar Singapore touchpoints, for orientation: Jollibee owns The Coffee Bean & Tea Leaf, controls Tim Ho Wan through an investment fund, and through a joint venture took Tiong Bahru Bakery and Common Man Coffee Roasters to the Philippines [5].

Around the flagship sits a portfolio built to cover the whole Filipino table: Chowking for Chinese-style fast food, Mang Inasal for grilled-chicken value, Greenwich for pizza, Red Ribbon for cakes and bread, together roughly 3,500 outlets. That breadth captures the eating-out peso across occasions and price points and gives the commissary the volume that makes it efficient. Stack the layers and the domestic moat comes into focus: a brand that is a cultural default, a portfolio that spans the table, a franchised structure that turns dominance into high-return royalties, and a supply chain that enforces quality while capturing manufacturing margin. It is the combination, not any single layer, that a competitor finds hard to match, and it still has room to run as the group pushes into higher-growth provincial markets behind new commissary capacity in the Visayas.

The pattern to carry forward is that all of this is local. Brand affection, portfolio breadth, franchised density and commissary scale are built on Filipino habit and Philippine geography, and those things do not travel. Everywhere except Vietnam, Jollibee competes abroad without the home-turf advantage, as one more challenger buying its way into crowded markets. That is the deeper reason the profit sits where it does.

The profit is still Philippine

Almost all of Jollibee’s profit is Philippine, a fact the “clean unlock” framing skates over.

The six-year record contains a violent shock and an incomplete recovery. Revenue fell to about ₱129bn in the 2020 pandemic year, when dining rooms shut and the group posted its first-ever annual loss, roughly ₱11.5bn. It then recovered hard, to ₱154bn, ₱212bn, ₱244bn, ₱270bn and ₱305bn in the five years to 2025, more than doubling the top line. The bottom line came back more slowly and has since flattened: net income to shareholders climbed from that loss to about ₱10.9bn, but the step from ₱10.3bn in 2024 to ₱10.9bn in 2025 was small, and momentum turned negative in early 2026. Reported profit is also flattered slightly by deferred tax assets recognised on the overseas units’ accumulated losses, an entry that lifts net income without adding a peso of cash, and one more reason to read the segment detail rather than the headline.

On the company’s own FY2025 geographic figures, the Philippine business earned about 112 percent of group net income to shareholders; the international arm, taken together, was a small net loss, about minus 12 percent. The overseas arm made an operating profit, roughly 19 percent of group operating income, but a net loss once financing and acquisition costs were counted, so the Philippine business had to out-earn the whole group to offset it. The pattern held the year before, at plus 111 and minus 11 percent, and it worsened at the net line in early 2026: in the first quarter the international operations lost roughly ₱0.7bn, about minus 52 percent of a depressed group net income, and attributable net income fell about 39 percent, to roughly ₱1.5bn [8].

The home engine is strong but maturing. Philippine same-store sales growth has stepped down from about 7.5 percent in 2024 to 5.2 percent in 2025 to 3.2 percent in the first quarter of 2026, the last against a base lifted by election-related spending, and domestic margins felt cost pressure early in 2026. This is a dominant, franchised, cash-generative business that is also slowing, not an annuity that compounds untouched, which is part of why management keeps reaching abroad.

The point this sharpens is what the separation actually is. It is not two profitable halves going their separate ways. It is a profitable Philippine business that has quietly subsidised a global build-out, and a proposed separation that would hand at least part of that build-out to public investors abroad. The question the rest of this piece works through is what the shareholder left holding the Philippine business receives in exchange, and what it costs to deliver.

The international arm is real, but mixed

This does not make the international arm bad. It makes it early, and real. International EBITDA grew about 20 percent in FY2025 to ₱14.1bn, its operating margin rose from 2.0 to 3.0 percent, and its share of group operating income climbed from 13 to 19 percent. The engine is coffee: of that ₱14.1bn, ₱8.6bn, more than 60 percent, is Coffee and Tea, led by Compose in Korea (EBITDA up 156 percent in its first full year inside the group), The Coffee Bean & Tea Leaf, and Highlands in Vietnam. Around it sit the newer Asian brands and a scatter of turnarounds still dragging, China (international EBITDA down 69 percent) and Smashburger (EBITDA of about minus ₱1.0bn) among them. Jollibee’s international business is, first and foremost, a coffee platform with a Vietnamese quick-service winner attached, not a scaled-down replica of the chicken chain at home.

One caveat on the brand itself, precisely because it is easy to overstate. Where the Jollibee brand has travelled abroad, it has historically done so on the back of Filipinos rather than by winning locals: its overseas stores cluster where the diaspora is thick, and the company’s own push to reach mainstream American customers concedes as much [9]. Vietnam is the telling exception, with only a small Filipino population but more than two hundred stores selling to local diners. Kept in proportion, this applies to the Jollibee brand abroad, a few hundred of the arm’s thousands of stores; the arm’s growth case rests on the acquired local brands, Compose, Highlands and The Coffee Bean & Tea Leaf, where Filipino demand is beside the point. The value is not the brand’s diaspora pull but the businesses it has bought.

Because the arm is bought rather than built, judging it means judging Jollibee as an acquirer, and the record is genuinely mixed. The domestic template worked: Mang Inasal, bought in 2010, became one of the group’s best growth engines, a heavily franchised grilled-chicken chain that still posts some of the fastest same-store growth in the portfolio. That is the template the bulls hope repeats abroad, buy a strong local concept and scale it through franchising, though the domestic deals had the home-turf advantages working for them, which is exactly why they are weak evidence for what happens overseas. Abroad the results are harder to read. Smashburger, the American “better burger” chain taken to full ownership by 2018, has underperformed for years and was still being reformatted in 2026; The Coffee Bean & Tea Leaf, bought in 2019, has been a turnaround more than a growth story; China has been a repeated cycle of openings and closures. Against those sit the clear winners, and they cluster in Asia and in the newest deals. Vietnam is the standout, with systemwide sales up more than 40 percent last year; Tim Ho Wan more than doubled its Hong Kong store count within a year of full integration; and above all Compose, bought in 2024 for about US$340m [6] at roughly eight times its annual operating earnings, grew its underlying product sales more than 10 percent in 2025 [15], even as its reported contribution to the group jumped far more on its first full year of consolidation. Tellingly, Highlands is pursuing a parallel Vietnam listing at a reported US$400m [7], a separate monetisation path that could complicate, or potentially thin, the eventual international perimeter, depending on how the two transactions are structured. The honest reading is that the arm is some winners and some turnarounds wearing a single growth label, and the separation is partly an attempt to let the market price the winners without the drag.

The exits tell their own story. Over the past decade the group has quietly walked away from a US subsidiary, China’s Dunkin’ and a hotpot venture, and Vietnam’s Pho24, none large alone but together the mark of a company that buys often and is willing to cut its losers. That is healthier than clinging to them, but it is not the effortless compounding the “global growth company” label implies. Compose is the counter-example the bulls lean on hardest: almost entirely franchised, close to debt-free and high-margin, it is the asset-light model the group wants to define its international future. And the buying has not stopped, which is a tell in itself. In February 2026, well into the “strategic review,” the group agreed to acquire the South Korean hot pot chain Shabu All Day for about US$87m [6], a second Korean deal in under two years that sits awkwardly against the idea that the arm is being frozen and readied for a clean carve-out.

Management knows this ceiling, and its answer is instructive. It has been expanding its US franchising programme, aiming for a majority-franchised American footprint and courting mainstream customers rather than only Filipinos [9]. That is a genuine point in the separation’s favour. The open question is whether the strong US unit economics the company advertises hold beyond a handful of high-traffic destination outlets in areas of dense Filipino settlement; that is the diaspora question restated, and we flag it as our reading rather than a proven claim, since we lack the store-level customer data to settle it either way.

All of this sits on the balance sheet as about ₱78.8bn of goodwill and brand intangibles, more than a quarter of the group’s total assets, the accumulated price of a decade of buying. It is not a cost that recurs, but it is capital that has to earn a return, and at the group’s net line the international business has not yet earned one on it. Judging Jollibee therefore means judging its record as a buyer, which is why the mixed record above weighs as much as the growth rate.

What the closest US-listed Asian precedents show

Here is the mechanism the bull case needs, stated plainly. Today the international arm is buried inside a Manila-listed chicken chain and the market gives it little; the whole company trades at roughly what the Philippine business alone is worth. Separate it, list it in New York where investors pay rich multiples for restaurant growth, and the same business re-rates to a US growth multiple. The gap between “nothing” and “US growth multiple” is the unlock, and the venue-driven bull narrative maps that supposed re-rating onto the gap between the current price and bullish valuation scenarios, from the consensus mean near ₱211 [1] to the ₱287 top of the current range and the ₱330-plus targets seen before the recent de-rating.

Everything hinges on one link: a US listing produces a US multiple. It is the single testable claim on which the whole bull case rests, and it has been tested, because several Asian restaurant and coffee companies have already reached a US exchange by different routes, and we can see what the market paid. The closest to Jollibee’s proposed transaction is Yum China, which Yum Brands spun off and listed on the New York Stock Exchange in 2016: a carved-out, Asia-focused restaurant operator, made independent and primarily US-listed. It is large, profitable, dividend-paying and cleanly run, and it trades at about 1.3 times sales and nine times EBITDA. A fresher test arrived in April 2025, when Chagee, a Chinese premium-tea chain, listed directly on Nasdaq in a primary IPO; it trades near 0.7 times sales. And Haidilao carved out its own international arm as Super Hi and added a Nasdaq line in 2024; it sits near one times sales. Three routes onto a US exchange, a spin-off, a primary IPO and a carve-out, and the same answer each time:

Read down the Asian names and the pattern is hard to miss: across these three precedents, the current valuations sit at roughly 0.7 to 1.3 times sales, while the American growth names command three to eight. Chagee is the sharpest test, and it cuts both ways. When it IPO’d on Nasdaq in April 2025 the market did hand it a substantial US-style listing premium, valuing it at roughly 2.4 times sales on an enterprise basis at its IPO price and nearer 3 times at the opening pop, depending on the treatment of its IPO cash; as its growth cooled, that premium drained away and it now trades near 0.7 times EV/sales, like the rest. So the honest lesson is not that a US listing can never confer a substantial listing premium, it plainly can at the moment of listing, but that the venue cannot sustain one the underlying economics do not support.

Each Asian name has its own story, Chagee’s cooling growth, Yum China’s China-market risk, Super Hi’s dual listing, and that is exactly why the pattern persuades: the explanations differ, but the durable multiple is missing in every case. We are not claiming the venue is worth nothing; a genuine US listing can add liquidity, disclosure and investor access, and the research on cross-listing premiums says those are worth something. We are claiming something narrower and sturdier: no plausible venue benefit durably turns a one-times-sales Asian platform into a five-times-sales American one. Absent materially better growth, margins and capital efficiency than it shows today, Jollibee’s coffee-led Asian arm belongs nearer one to two times sales than to the multiples of US growth chains. The re-rating the bull case needs is the part that does not last.

There is a real limitation to this comparison, and it is worth stating plainly. Each of the three closest US-listed precedents used here is Chinese or Chinese-origin: Yum China operates almost entirely in China, Chagee is a Shanghai-based chain, and Super Hi is the carved-out international arm of a Chinese hotpot operator. Part of their discount may therefore be China-specific, reflecting US-China delisting risk, governance perceptions around Chinese issuers, capital controls and single-market concentration, rather than a generic Asian penalty. Jollibee’s arm is Philippine-controlled and spread across Korea, Vietnam, China and North America, and could on that basis command a somewhat higher multiple than a pure-China name. So our claim is not that these precedents prove an immutable Asian ceiling. It is narrower and harder to dispute: they offer no support for assuming an automatic leap to US growth-chain valuations, and any durable premium Jollibee’s arm earns will have to come from its own growth, margins and capital efficiency, not from the ticker. On that score its own record, loss-making at the net line, minority-laden and built by acquisition, argues for caution rather than a premium.

So a US listing crystallises value without multiplying it. That leaves the two questions that decide whether the stock is actually cheap: what are Jollibee’s parts really worth, and how much of that ever reaches the person holding the shares in Manila?

Below, for paid subscribers: the sum-of-the-parts, and how far the per-share value drops once the arm carries its real share of JWPL's debt; the leaks between enterprise value and a Manila shareholder's pocket; the bull case at full strength; and the evidence that would prove us wrong.

Read more

That is the demand backdrop for Singapore’s largest home-grown recruiter, and it shows up in the filings with some precision. HRnetGroup’s gross profit from its Singapore operations has now fallen for four consecutive years. In FY2025 it dropped another S$4.1 million. The company still reported its highest net profit since FY2023, S$51.2 million, up 15% year on year. Both of those statements are true at the same time, and reconciling them is the entire exercise.

The headline most readers will have seen is the one about the cash. Management describes a “cash moat” of about S$336 million, which against a market value of roughly S$737 million is a striking figure: close to half the company’s market capitalisation sits in cash and near-cash. The number is real. What is less examined is how much of it a minority shareholder can actually reach, what the operating business looks like once you strip the income that cash throws off, and whether the dividend that pays you to wait is as secure as the balance sheet makes it look.

Those questions live in the segments, not the headline profit. We start there.

How the Company Was Built

HRnetGroup was founded in Singapore in 1992 by Peter Sim, who remains executive chairman at roughly 73 years of age and who, his daughter notes, “has always said he wants to work until he’s 100.” [1] The business began as a single recruitment firm and grew into what the company describes as the largest Asia-based recruitment agency in the Asia-Pacific outside Japan, operating today across 18 Asian cities.

The structural decision that defines the company came early: the co-ownership model. Rather than running branches staffed by salaried managers, HRnetGroup makes its senior people part-owners of the specific city-business they run. These “Business Leaders” hold equity in their own units; their appointments are disclosed individually through SGX filings, and by April 2026 the count had reached 47, up from 22 at the 2017 IPO. Management attributes the company’s consistency, having stayed profitable through every major crisis in its 33-year history, to this structure, and the mechanism is plausible: the people generating the gross profit have a direct claim on it and a strong reason not to leave. We cannot prove the model caused the profitability rather than accompanying it, but it is the most credible explanation on offer, and it is the organising principle of the whole company.

HRnetGroup listed on the SGX mainboard on 16 June 2017 at an offer price of S$0.90, opening at S$0.95. It was nearly a Hong Kong listing instead. By Adeline Sim’s account, cornerstone investors offered the same valuation in either venue and the family chose Singapore because it is headquartered there: “why not be where we are wanted.” [1] The stock has spent most of its listed life below its offer price, touching an all-time low of S$0.41 in March 2020 during the COVID crash and, on management’s own description, hovering between 75 and 80 cents since mid-2021. [1]

Gross profit plateaued at its peak across FY2021 and FY2022, S$174.9 million and S$174.2 million respectively, with attributable profit around S$67.5 million in FY2022, a figure Adeline Sim confirmed directly in a July 2024 interview. [2] What followed was a sustained decline in the core business that the headline profit number has since partly masked. Gross profit fell to S$139.0 million in FY2023, then S$122.2 million in FY2024, and was essentially flat at S$122.9 million in FY2025. That is a 29% fall in gross profit from the peak. Net profit fell less dramatically, from S$67.5 million to a low of S$44.5 million in FY2024, before recovering to S$51.2 million in FY2025, and the reason it recovered is the heart of this article.

The most recent piece of corporate history is the September 2025 incorporation of AllwaysFirst in Ho Chi Minh City, the group's 18th city and its entry into Vietnam, a wholly owned subsidiary focused on professional recruitment in technology. [4] Management has said directly that "any immediate contribution from the new subsidiary may not be material." [4] We treat it accordingly.

What the Company Actually Does

HRnetGroup sells two things, and they look almost nothing alike in the accounts.

The first is Professional Recruitment, the placement of permanent staff, typically mid-to-senior white-collar roles. The company is paid by the employer, not the candidate, and the standard form is a one-time placement fee set as a percentage of the successful hire’s first-year remuneration. Most of that work is contingency-based, meaning the fee is earned only if the client actually hires the candidate, with senior executive search more often run on staged retainers. In FY2025 this segment produced revenue of S$55.8 million and gross profit of S$55.6 million. The reported gross margin of about 99.6% is an accounting artefact, not an economic one: in permanent placement there is no separately allocated cost of sales, so the fee is essentially all “gross profit,” and the cost of the consultants who earn it sits below the gross-profit line as employee expense. The consultant who makes the placement is paid a base salary plus commission on the fees they bring in, and under the co-ownership model the Business Leader running that desk owns a share of the unit’s profit, which is the alignment mechanism described earlier. So the right way to judge this segment is not its headline margin but its gross profit per consultant and its placement volume. On that basis FY2025 was flat: PR gross profit grew S$0.7 million, or 1.3%, and placement volumes were modest. This is the high-margin, cyclical engine, and right now it is idling.

The second is Flexible Staffing, the supply of contract and temporary workers, where HRnetGroup employs the worker itself and bills the client. The economics are a spread: HRnetGroup pays the contractor a wage and bills the client a charge rate set above it, keeping the difference. The contractor wage is the cost of sales here, which is why the FY2025 gross margin was only 12.2%, down from 12.6%, against the near-100% optical margin of permanent placement. Because HRnetGroup pays the worker before the client pays HRnetGroup, it also funds the payroll float across a one-week-to-two-month billing cycle, so this engine ties up working capital as well as earning a thinner margin. In FY2025 it produced revenue of S$524.1 million, up 3.2%, and gross profit of S$63.8 million, down marginally. This is the lower-margin, higher-volume, more defensive engine. It is also where Singapore's weakness is most visible, because Singapore is where most of the flexible-staffing book sits.

A third line, reported as "Others," houses Octomate and assorted payroll and employer-of-record services. It produced revenue of S$4.1 million, broadly flat, and gross profit of S$3.5 million, up about 7%, in FY2025. Octomate is a cloud workforce-management and instant-payment platform that HRnetGroup took a 51% stake in during October 2022; its payment engine integrates with HRnetGroup's own Ease Works app to give contractors earned-wage access the moment a timesheet is approved. [3] Daily active users have grown from about 3,000 at acquisition to, on the company's own reporting, roughly 15,000 by January 2026 [14], with Amazon, H&M and Hyundai among named users. [3] We read Octomate less as a standalone software business than as an internal tool that lowers friction and supports retention in flexible staffing, which is why the flat "Others" revenue (a line that also bundles payroll outsourcing and employer-of-record services) is probably the wrong test of its value. Either way we attach no number to it, and the investment case does not need it.

A client has alternatives, and they differ by segment. For permanent recruitment it can run the search in-house, use a rival agency, or lean on AI sourcing tools. For flexible staffing, which is closer to a commodity, large clients run vendor-management systems that pit suppliers against each other on price, or bring payroll in-house. That commodity dynamic is what the 12.2% flexible-staffing margin, and its slippage, looks like in the accounts. What actually defends the business against these alternatives, and where AI helps rather than hurts, is the subject of the moat section.

Geographically, FY2025 is where the real story sits.

Read across the bottom row first. Group gross profit grew S$0.7 million, six-tenths of one percent. Now read the column above it. Singapore gross profit fell S$4.1 million. Everything outside Singapore grew S$4.8 million, almost exactly offsetting the decline. That near-perfect cancellation is the company in FY2025: a shrinking home market held level by a growing regional one. The blended gross margin outside Singapore, about 27.3%, is materially higher than Singapore’s 17.3%, so as the mix shifts away from Singapore the group’s average margin quality improves even when total volume does not. That improvement is not purely geographic, though. North Asia’s higher margin reflects a heavier weighting to permanent recruitment, which carries a near-100% accounting margin, while Singapore’s lower margin reflects its heavier flexible-staffing mix at about 12%. So the shift out of Singapore is also a shift from lower-margin, defensive flexible staffing toward higher-margin but more cyclical permanent recruitment. That lifts margin quality and, at the same time, makes the earnings mix less defensive than the income framing implies. It is also the only thing standing between the group and an outright decline in gross profit.

The last structural fact a reader needs concerns the treasury, because it dominates the valuation. We deal with the precise composition in the investment case. Here we state only what it is: as at end-FY2025 the group held S$262.9 million of cash and equivalents, plus credit-linked notes and government securities of S$62.7 million and S$10.7 million of gold and commodity-linked assets, which management aggregates to a “cash moat” of about S$336 million. [1] Strategically held quoted equities are excluded from that figure. There is no bank debt. The only borrowings are S$14.7 million of lease liabilities under accounting rules for office space.

The Industry: A Cycle Down and a Structural Question

Two forces act on this business, and they should not be confused. One is cyclical and global. The other is structural and local.

The cyclical force is the worldwide downturn in professional recruitment that began after the 2021 to 2022 hiring boom. It is not specific to HRnetGroup, and the peer numbers make that clear. Hays, the UK-listed global recruiter, reported net fees (its term for gross profit) of £972.4 million for the year to June 2025, down 13% year on year, and cut its core dividend by 59%. [7] PageGroup reported gross profit of £769.5 million for 2025, down 7.6%, with operating profit down 59%. [8] Robert Half’s revenue fell 7.2% to US$5.38 billion, with operating income down roughly two-thirds. [9] Against that field, HRnetGroup’s flat gross profit is, relatively, a good outcome: it held up better than the three large global recruiters, though not better than Staffline, which grew gross profit 10.6% after restructuring out of a loss-making division. [10]

The structural force is the one that should hold an investor's attention, because it is specific to where HRnetGroup makes most of its money. Singapore gross profit has fallen for four straight years. The proximate cause in FY2025 was a soft labour market: by the first quarter of 2026, Singapore job vacancies had eased to 73,300 from 77,700 three months earlier, the ratio of vacancies to unemployed persons had slipped to 1.46 from 1.58, and the share of firms expecting to hire in the next three months had dropped sharply, from 54.6% in February to 44.6% in March. [12] A forward-looking read points the same way: employers' net hiring outlook for Singapore in the third quarter of 2026 fell to 13%, down 11 points both on the quarter and on the year, with the decline led by large organisations, whose outlook was a net negative 26% on what the survey calls optimization-led consolidation. [22]

That is cyclical softness. But layered underneath it is something management describes as a change in kind, not degree: AI is making clients more selective about whether a role exists at all, undercutting even the old labour-arbitrage logic of sending a Singapore role to a cheaper market. [1] AI cuts both ways for a recruiter, though, and we should be even-handed about it. It automates the junior, high-volume, searchable end of hiring and lets large clients source directly, which is a real threat; but it raises the value of agencies at the other end, in senior and specialist search where relationships matter, and in candidate verification, as AI-generated CVs, forged credentials and deepfake interviews make trust scarcer. [17] Which side HRnetGroup lands on depends on whether it keeps migrating its gross profit toward the specialist end, which is the stated aim of its senior-executive pivot.

One caution on the labour read: the easing in Singapore vacancies through early 2026 was concentrated in non-PMET roles, while professional and technical roles actually became harder to fill, so aggregate labour softness does not by itself prove that professional-recruitment demand is structurally weakening. [18] We cannot prove from filings how much of Singapore's decline is cyclical and how much is permanent, and we treat it as structural in the base case until the company shows stabilisation.

The offset to Singapore is geographic, and it is shifting the group's centre of gravity: North Asia's share of gross profit is rising as Singapore's falls, and it earns far more per dollar of revenue than the home market. North Asia spans seven mainland Chinese cities, the three Taiwan cities, Hong Kong, Tokyo and Seoul. The overseas shift is contractor-led: average monthly contractors rose 5.6% to 16,421, the increase coming from Taiwan, Indonesia and Mainland China (Indonesia sits in Rest of Asia) while Singapore's headcount fell. North Asia specifically drew stronger professional-recruitment placement activity in Taiwan, Mainland China and South Korea, with Thailand and Malaysia adding to the wider offset against a softer Singapore. Group-wide, demand is spread across industries rather than concentrated in any one: IT and technology is 24% of the business, of which 12% is AI-related roles, financial and insurance about 21%, and healthcare and life sciences and retail and consumer roughly 14% each. On the group's own brand job boards the overseas book runs the full range, from operational and retail staffing to executive search. [13] Rest of Asia contributed too, off a small base, with Vietnam a new market.

One scheme-level detail matters and is easy to get wrong. Singapore's Progressive Wage Credit Scheme, under which the government co-funds wage increases for lower-paid local workers, pays HRnetGroup meaningful grant income, and it runs through 2028: Budget 2026 set the co-funding rate at 30% for 2026 and 2027 wage increases, and 20% in the final year, 2028. [11] So the scheme is supported, not tapering, over the next two years. Why the S$9.2 million FY2025 grant figure still overstates the recurring level, and how that feeds the valuation, is in the normalised-earnings section.

The Moat: What Is Real and What the Numbers Will Not Support

A company with this balance sheet and this dividend invites the assumption that it must have a strong competitive position. Some of that assumption is warranted. Some of it is contradicted by the company’s own gross-margin history.

What is defensible is the co-ownership model. Making Business Leaders part-owners of their city-units creates retention a branch-and-salary rival cannot easily copy, because what holds a team in place is equity in the unit, not a salary another firm can beat. The observation the bullish reading skips is that the model has a recurring cash cost: recycling ownership interests as Business Leaders join, leave or change stakes consumed S$3.3 million in FY2025. The alignment is genuine; it is not free.

Also defensible, though not measurable from filings, is network depth in specific niches, executive and professional search in Hong Kong and mainland China, the breadth of an integrated group of around twenty brands spanning executive search, flexible staffing, employer-of-record and payroll across 18 Asian cities, and reach into the people who are not actively looking. Management's claim, which we cannot verify from the filings, is that roughly 90% of strong performers are not job-hunting, so the value is in knowing and attracting them. [1] This is also where AI sorts the business rather than simply threatening it: it commoditises the junior, high-volume, easily-sourced end, where clients can self-serve, and spares senior and specialist search, where the relationship still carries weight, which is the stated reason management is moving up-market toward C-suite roles. External evidence points the same way: in the same employer survey, having a person review resumes ranked as the most valued hiring resource, above AI screening and sourcing tools, consistent with the relationship end of recruitment holding its value even as the high-volume end is automated. [22]

The third advantage is the balance sheet, and it is the most concrete. The cash position lets HRnetGroup fund the contractor float described earlier, win large contracts capital-light competitors cannot, and acquire without raising money. Trade receivables of S$93.9 million carry a loss allowance of only S$104,000, consistent with strong collection history and a generally creditworthy client base. Part of that quality is structural: public-sector clients, which carry no credit risk, are 16% of revenue and rising, no single customer is a tenth of revenue, and the top five clients, at 17.2% of revenue between them, have been with the group an average of eighteen years. Ample working capital plus exceptional credit quality is a competitive advantage, not just a defensive buffer. In flexible staffing, which has the thinnest moat because the service is close to a commodity, these are the real defences, scale, the compliance and payroll machinery, and the capacity to fund contracts a thin rival cannot; and the cross-cutting AI disruption is met on the technology side through Octomate, the internal tool described earlier, rather than only absorbed.

What the record will not support is the claim that brand or scale protects pricing. Group gross margin has fallen from 29.6% in FY2021 to 21.0% in FY2025. That is not the margin path of a business with pricing power. Some of the fall is mix, as lower-margin flexible staffing grows relative to high-margin permanent placement, and some is genuine competitive and AI-driven pressure on the Singapore core. Either way, an 8.6 percentage-point gross-margin decline over four years is the single fact that disciplines any moat argument here. The advantages above are real. They have not prevented margin compression, and an honest moat assessment has to hold both ideas at once.

The Financial Scoreboard

Every figure below is from the company's filings, including the audited FY2021 results; FY2022's S$67.5 million attributable profit was confirmed by management directly. [2]

The shape is clear without commentary. Revenue has been range-bound around S$580 to S$610 million for five years. Gross profit and gross margin have fallen steadily. Net profit fell to FY2024 and then recovered in FY2025. The dividend has been held at 4.0 cents for four years and was raised to 4.2 cents for FY2025. A company that grows revenue slightly, earns less gross profit each year, and still raises the dividend is telling you where its priorities sit, and where the risk sits too.

Returns on Capital, Read Two Ways

On a reported basis, FY2025 return on equity was S$51.2 million of PATMI on S$402.1 million of equity attributable to owners, about 12.7% on year-end equity (13.1% on average); total equity including S$12.0 million of non-controlling interests was S$414.1 million, and we use the attributable figure throughout. That 12.7% misleads in two directions. The equity base is inflated by the treasury: roughly S$270 million earns a low yield and does almost nothing for operating returns, so the underlying operating business, which is capital-light, earns far more than 12.7% on the little capital it actually uses. Pulling the other way, the S$51.2 million is flattered by non-operating income; on normalised attributable profit of about S$38.3 million (the bridge is built in the investment case below), return on attributable equity is about 9.5% year-end, or 9.8% on average, and it is earned by a business whose gross profit has not grown in two years.

So the capital story is two-sided: a high-return operating business sitting inside a company whose blended return is mediocre because most of its capital is idle cash. Which fact matters depends on whether that idle cash ever returns to shareholders, the governance question we take up below and do not resolve in the company’s favour.

What Management Does With the Cash

For a company defined by its balance sheet, the record of what it actually does with capital is more revealing than any statement of policy, so we pulled it from the share-capital note and the statement of changes in equity rather than the headline tables.

The dividend is the primary channel and it is consistent: 4.0 cents held through FY2022 to FY2024, raised to 4.2 cents for FY2025, with a one-cent special paid in FY2021 on top of the ordinary 4.0. Cash dividends paid have run between roughly S$39 million and S$40 million in the last two years, with a higher figure of about S$52 million passing through FY2023 on dividend timing. The payout has absorbed roughly 80% of reported earnings each year.

The buyback channel tells a more pointed story. The S$30 million programme launched in June 2022, near the price the stock still trades around, and the spend has fallen every year since, to just S$0.9 million in FY2025; cumulatively S$19.7 million of the S$30 million programme is used, S$10.3 million unspent. More striking, FY2025 was a net-seller year: against S$0.9 million repurchased, the company sold S$7.2 million of treasury shares, principally the October 2025 placement of 9,780,800 shares at S$0.714 to enhance liquidity and free float following a reverse inquiry. [15] The liquidity rationale is real, and a discounted placement does not by itself mean management judged S$0.714 to be fair value. But it sits awkwardly beside the rhetoric: a company that calls its shares undervalued, holding cash worth close to half its market value, was adding to supply at a discount while its buyback programme sat idle.

Keep the facts, the explanation, and the inference apart. The observed facts: the company distributed about 80% of earnings as dividends, reduced its buyback spend every year to near zero, was a net seller of its own stock in FY2025, and retained S$336 million on the balance sheet, deploying capital into growth only at the small scale of the September 2025 Vietnam start-up. Management's stated explanation is that the treasury is strategic optionality it intends to keep rather than distribute. Our inference, labelled as such, is that the declining buyback and the discounted placement are hard to reconcile with a strong conviction that the shares are cheap, and that the treasury looks retained for the long term rather than positioned for near-term return to minorities. On the facts as they stand, a minority's return comes from the dividend and operating progress, not from the treasury being put to work on their behalf, and nothing in the record points to that changing without a decision only the family can make.

The Investment Case

The central tension: reported profit versus the operating reality

In FY2025, PATMI, the profit attributable to owners of the company, rose 15.0%, from S$44.5 million to S$51.2 million. Gross profit rose 0.6%. A business whose gross profit is flat does not generate a 15% rise in attributable profit from operations. The increase came almost entirely from below the gross-profit line,

Read more

Somewhere in a Singapore operating theatre this week, a surgeon will inject a few milligrams of green powder dissolved in sterile water into a patient’s bloodstream. Under a near-infrared camera, the compound, indocyanine green, will light up the patient’s blood vessels and tissue perfusion in real time: a glowing map of where blood is flowing and where it is not. The surgeon uses that map to decide where to cut, what to reconnect, and whether a newly joined section of bowel will survive. The dye has been in clinical use since the 1950s. The camera, the regulatory approvals, the distribution network and, increasingly, the data captured around each procedure belong to a company most Singapore investors had never heard of before December 2025.

UltraGreen.ai Limited listed on the SGX Mainboard on 3 December 2025 at US$1.45 per share, the largest non-REIT listing in Singapore since 2017 [12]. It sells roughly 83% of all indocyanine green (”ICG”) vials used in the United States and about 94% of those used in Europe, with no approved substitute for the fluorescence-guided surgery (”FGS”) indications it dominates [2]. It earned an 85.0% gross margin in FY2025. Its revenue has compounded at 43% a year since FY2022. As at 10 June 2026 the shares trade at US$1.42 [1], 2% below the IPO price and 24% below the February peak of US$1.86.

The market’s implied verdict is that this is a fully priced, mid-growth medtech: at US$1.42, roughly 18x our estimate of FY2026 earnings, against the premium multiples global medtech peers command, which published comp sets put anywhere from about 20x to 32x forward [8]. We think that verdict rests on a misreading of one income statement. FY2025’s reported numbers simultaneously overstate the group’s tax burden, through a one-time US$8.5 million provision that is the subject of a pending exemption application, and understate its interest income, because the US$150.0 million of IPO proceeds arrived in the final month of the financial year and earned almost nothing. One distortion reverses mechanically in FY2026; the other awaits a ministerial ruling, with both outcomes computable today. Together they could add roughly US$13–15 million of net profit, a 20–24% uplift on the underlying FY2025 base of US$63.8 million, before a single additional vial is sold.

This article works through three questions in sequence. First, are FY2025 earnings temporarily depressed? We will show the arithmetic says yes, and quantify it. Second, does UltraGreen’s US pricing hold through the hospital purchasing cycle? That is genuinely open, and we will name the one undisclosed variable that matters most. Third, can the ICG cash engine fund a credible platform business in data and imaging? That is conditional, and we will treat it as optionality rather than earnings. Along the way we will also explain why the share price fell 24% from its peak, why we think much of that fall was macro rather than company-specific, and what one number, due in August 2026, would make us abandon the thesis entirely.

From Frame Relay to fluorescent dye

Ravinder Sajwan, 64, did not invent anything UltraGreen sells. That is worth stating plainly at the outset, because the company’s moat makes more sense once you stop looking for the patent. Sajwan’s career is a Silicon Valley operator’s résumé: a 2,400bps modem design early on, a universal network-testing device acquired by Tektronix, senior technical roles at StrataCom, whose Frame Relay technology Cisco bought for US$4 billion in 1996, then the co-founding of Acclaim Communications, sold to Level One for US$120 million in 1998, shortly before Intel bought Level One for US$2.2 billion [3][19]. Between telecoms and medtech came a long, lucrative interlude producing 5-Hour Energy drinks, a business connected to founder Manoj Bhargava, which threw off dividends that capitalised the family’s Renew Group [3].

The ICG story began, by Sajwan’s own telling, around 2013, when he encountered the dye through a German medical device company using it to measure holes in hearts [3]. What he saw was not a molecule but a market structure. ICG itself is an old, unpatentable compound; Sajwan has compared it to matcha powder, an everyday-seeming ingredient with an outsized value per use [19]. The product is cheap to make, sells for a small fraction of the cost of the surgery it supports, and is protected not by intellectual property but by regulatory approvals, manufacturing accreditation, distribution relationships and surgeon habit. From 2015, Renew built UltraGreen by buying, partnering with and consolidating the companies that held those positions: the moat was assembled, not invented [3]. The group even founded the International Society of Fluorescence-Guided Surgery, a surgeon education body that, whatever its scientific merits, functions commercially as a standard-of-care flywheel for ICG procedures [19].

The capital structure history matters for what comes later in this article, so we set it out here. UltraGreen took no outside investors at all until 2025, when 65 Equity Partners (a Temasek-backed vehicle investing from a fund with an explicit mandate to groom companies for SGX listings) and Vitruvian Partners invested in a pre-IPO round [10]. Before that, in November 2024, the company issued a US$142.8 million promissory note to its immediate holding company RGPL, in effect a distribution to the controlling shareholder funded by an IOU, which pushed group equity negative (total equity at 31 December 2024 was negative US$26.0 million). In August 2025, the note was settled by issuing RGPL 142.8 million new shares at US$1.00 apiece. In the same pre-IPO window the company paid US$39.8 million of FY2025 dividends to its pre-listing shareholders and sold its UltraLinQ cardiology software business for a US$23.7 million gain. Then came the December IPO: US$150.0 million of primary proceeds at US$1.45 per share, within a roughly US$400 million total offering including a US$237.5 million cornerstone tranche taken up by sixteen institutions, among them abrdn, AIA, Eastspring and Lion Global [11][12].

The debut was respectable but not euphoric: the stock opened at US$1.51, touched US$1.62 intraday, and closed at US$1.52 [12]. Within nine trading days it was at US$1.31, and the stabilising manager deployed its full 20.7 million share mandate; the over-allotment option was never exercised [13]. The stock then rallied to US$1.86 by 23 February 2026, sold off through a risk-averse March, and slid to a US$1.20 low in late May after a first-quarter print the market misread [7], both of which we return to below; it sits at US$1.42 as we write [1]. A listing that was priced at 28.6x FY2024 earnings [12] now trades, on our normalised arithmetic, at a multiple in the high teens against earnings that have since grown.

What the company actually sells

UltraGreen is best understood as three layers stacked on one molecule.

The first layer is the dye itself, and it is almost the whole income statement today. The group sells ICG vials under the IC-GREEN brand in the US and Verdye elsewhere, through two geographic segments. DxG–Americas generated US$106.5 million of net revenue in FY2025, 74.8% of the group total, up 23.9% year on year. DxG–Rest of the World generated US$31.0 million, up 40.7%. Volumes tell the same story with less noise: 667,800 vials shipped in the Americas in FY2025 and 319,900 elsewhere, 987,700 in total, up 13.2% on FY2024. Cumulatively the group had sold about 5.3 million vials since 2015 as at June 2025 [11]. Gross margin on all of this was 85.0% in FY2025, up from 75.5% in FY2022, a function of price increases falling through to a largely fixed cost of goods.

The second layer is hardware: the IC-Flow imaging system, a handheld near-infrared camera that makes the dye visible. UltraGreen’s German subsidiary Diagnostic Green GmbH is the license holder and manufacturer of record. The camera is not currently a profit centre; it is an ecosystem device, and the group’s Asia strategy makes that explicit. In Asia, UltraGreen will lease cameras to hospitals rather than sell them, lowering the entry cost for adoption while keeping the recurring vial sales and, importantly, the procedure data [10]. Camera manufacturing is being relocated from Germany and Ireland to Singapore, at the group’s MacPherson headquarters [10]. Commercial responsibility is split between two Chief Commercial Officers, one for the Americas and one, Fidelma Callanan, based in Ireland, covering everything else; the Asia build-out reports to her [10].

The third layer is the platform ambition that justifies the “.ai” in the name: the UltraGreen Data Platform, the PerfusionWorks perfusion-analytics software acquired with Denmark’s Perfusion Tech ApS (the remaining 72.6% was bought in June 2025 for US$5.6 million net of cash, adding US$3.7 million of goodwill and US$8.2 million of intangibles), and a small UltraGreen Data Systems (”UGDS”) segment created in 2025 from retained UltraLinQ staff. UGDS also distributes biosensor products from LifeSignals Inc., an associate of the controlling shareholder’s private group, a related-party arrangement we examine in the governance section. The platform layer is currently a cost: UGDS recorded US$0.4 million of revenue and a US$1.6 million operating loss in FY2025, and PerfusionWorks is targeted for commercial launch in 2027, a management target rather than a committed date. The regulatory groundwork is further along than the revenue line suggests: the IC-Flow system and the UltraGreen Data Platform carry US 510(k) clearance and CE marking, and PerfusionWorks has been filed for approval in Europe, with management indicating a potential European launch as early as 2026 and progress through the EU MDR and FDA pathways during the year. In April 2026 the group also branded its cardiology distribution business UltraGreen Cardiac Technologies, the commercial wrapper for the LifeSignals biosensor arrangement. There is also Ferronova, a 26.9%-owned Australian associate developing iron-oxide nanoparticle devices for sentinel lymph node biopsy, an adjacent modality that costs the group roughly US$0.5 million a year through the associates line. We note it here and set it aside: it is not material to the valuation.

One business is deliberately absent from this list. UltraLinQ, the cardiology image-management software the group sold in August 2025 for a US$23.7 million gain, contributed US$4.4 million of revenue in FY2025 before disposal and US$6.7 million in FY2024. Reported FY2025 revenue of US$142.4 million therefore overstates the continuing perimeter; the comparable core figure is US$137.9 million. We use the core figure throughout this article when we discuss growth.

The industry: a standard of care still in its first quarter

Fluorescence-guided surgery is one of those rare medical technologies whose clinical evidence base is enormous while its adoption remains shallow. More than 20,000 peer-reviewed publications and over 780 clinical trials involve ICG [5], and the dye has US FDA approval history stretching back decades. Yet FGS penetration is still below 25% of addressable procedures in the United States, and lower again in Asia-Pacific [8]. At UltraGreen’s April 2026 AGM, the CEO put the addressable market for just the four core procedures, laparoscopic cholecystectomy, colorectal surgery, breast sentinel lymph node biopsy and breast reconstruction, at roughly 10 million surgical procedures a year, of which the group currently serves a small fraction, with procedure growth running at mid-to-high single digits. Frost & Sullivan frames the same runway in dollars: it sizes the global ICG market at about US$173 million in 2024, against a total addressable market of roughly US$925 million were FGS and ICG adopted across every eligible procedure, which leaves the category only about 19% penetrated [2].

The competitive map is unusually concentrated. By Frost & Sullivan’s count, UltraGreen held about 68% of the global ICG market by vials and 63% by revenue in 2024, with 83% of US vials and a 94% share in Europe [2]; Sajwan has put the US figure at 85% in interviews [3]. The company’s revenue is roughly 2.6 times that of the second-largest player [18]. In the US, the remaining ~17% of the vial market belongs to Stryker Corp, the Michigan-based devices group [4]. Daiichi Sankyo, the original Japanese incumbent, retains only a minor global role [4]. There is no other FDA-approved fluorescent agent for the broad FGS indications ICG covers; emerging agents target specific procedures, and management’s stated view at the AGM was that ICG’s safety profile keeps it the default across the majority of use cases.

Two industry developments in 2026 bear directly on the investment case. The first is regulatory: UltraGreen’s approval footprint expanded from 35 territories in 2024 to 45 by mid-2026. The composition of those approvals deserves precision, because dye and camera travel on separate regulatory tracks. The Verdye dye itself was approved in the Philippines (December 2025) and Singapore (May 2026); the March 2026 four-country sweep across India, Thailand, the Philippines and Bangladesh, like the December 2025 Malaysia clearance, covers the IC-Flow V2 imaging system, with the dye still to follow in most of those markets. The camera approvals lay regulatory groundwork; meaningful revenue in those territories waits on the corresponding ICG registrations, and the company says approvals are being sought in roughly 20 further markets across Asia and the Middle East. Asia is the growth frontier, and the entry indications are deliberately chosen for emerging-market epidemiology: diabetic foot ulcer assessment and lymphedema, ahead of the surgical oncology uses that dominate Western volumes. Sajwan’s framing of the wound-care opportunity is worth quoting: “Five per cent penetration of the diabetic foot ulcer market is twice our current total addressable market.” [9]

The second development is the misfortune of the only US competitor. On 11 March 2026, a hacking group calling itself Handala, claiming Iran-linked motives, attacked Stryker’s Microsoft IT environment; the company’s SEC filing disclosed disruption to order processing, manufacturing and shipping [20]. Recovery was quick by the standards of such incidents: electronic ordering was restored for customers by 26 March, with most manufacturing sites and critical lines back and order reconciliation still under way [21], and by 9 April the company reported itself fully operational [25]. Brief as it was, the disruption was not trivial: Stryker’s amended SEC filing formally determined the incident had a material impact on its first-quarter 2026 operations and financial results, while leaving full-year guidance intact [25]. Hospitals buying a consumable that sits on the critical path of scheduled surgery prioritise supply reliability above almost everything, and a two-week ordering outage is long enough to force substitution decisions. We treat the possibility that displaced Stryker orders flowed to UltraGreen as a hypothesis bounded by that two-week window, to be tested by the next volume print, not as an accrued benefit; the timing arithmetic is in the deep dive. But the episode illustrates the asymmetry of this market: when 83% leans on 17%, disruption at the small player consolidates the large one.

The moat: three layers, one weak seam

Asserting a moat is cheap; the financial record either corroborates it or it does not. UltraGreen’s record corroborates three distinct layers of advantage, and exposes precisely where the structure is least tested.

The first layer is regulatory and clinical entrenchment. ICG is not proprietary, and management says so plainly: at the April 2026 AGM the CEO identified the group’s advantages as its regulatory approvals, manufacturing processes, ownership of the FDA drug master file, and accumulated clinical data, not the molecule. A would-be competitor needs an approved abbreviated new drug application, accredited sterile manufacturing, and a reason for surgeons to switch a consumable that costs a rounding error within a surgical bill. IC-GREEN has been FDA-approved since 1959 and remains the Reference Listed Drug other ICG products are measured against (we develop this point, and what the FDA register shows about would-be generics, in the risks section), and the publication and training flywheel around the group’s surgeon society raises the switching bar each year.

The second layer is distribution. In the US, the Big Three pharmaceutical wholesalers, Cencora, McKesson and Cardinal Health, collectively accounted for 67.8% of group revenue in FY2025. We will argue later that this concentration is more benign than it looks, because wholesalers are logistics and credit conduits rather than buyers with pricing power. But as a barrier it is real: shelf position inside the ordering systems of effectively every US hospital is something a new entrant cannot replicate quickly at any price.

The third layer is the one the income statement proves: pricing power, exercised in three rounds and absorbed each time. UltraGreen raised US prices by an average of 60% per vial in August 2023 and another 30% in April 2024, then implemented a further round of US pricing initiatives in the third quarter of 2025 that lifted US average selling prices 22% to about US$158 per vial that year. Over the period the global blended ASP went from US$70.3 per vial in FY2022 to US$139.3 in FY2025 [4], and volumes did not fall; Americas vials grew from 470,400 in FY2022 to 667,800 in FY2025, and total vials from 699,600 to 987,700. A 98% cumulative increase in the blended ASP met 41% volume growth over the same three years. Demand for ICG is, on this evidence, about as price-inelastic as consumables get, which is what you would expect for a product that enables a procedure billed at two or three orders of magnitude above the vial price.

The weak seam runs through the second and third layers where they meet:

Read more

Walk into the Rolex boutique on the casino floor at Crown in Perth, or into Tong Building at the top of Orchard Road in Singapore, and the experience is engineered to feel timeless. A salesperson who knows your collection. A display of steel sports models you cannot simply buy off the shelf. A waiting list that is itself a status object. None of it looks like a listed company, and that is the point. The business behind that boutique floor is one of the oldest continuously operating luxury watch retailers in Asia, and it has been run by the same family for forty-six years.

The Hour Glass Limited (SGX:AGS) was founded in 1979 by Dr Henry Tay and Dato’ Dr Jannie Tay. It listed on the Singapore Exchange in 1988 and has not raised a dollar of equity from public markets in more than three decades. For the financial year ended 31 March 2026 it earned a headline net profit of S$179.5 million on revenue of S$1,338 million, both records, and it closed the year with no bank debt or bonds for the first time in at least a decade. Its book value per share has risen every single year for seven consecutive years, from S$0.86 to S$1.67. At the 3 June 2026 close of S$2.63, the market values the whole company at roughly S$1,685 million.

The most interesting fact about The Hour Glass right now is the acquisition it completed in 2025, and the reason the seller gave for selling. In a deal worth AUD90 million, The Hour Glass bought THGRAU, the Australian Rolex authorised-dealer business previously owned by Kennedy Watches & Jewellery: four Rolex flagship boutiques in Melbourne, Sydney and Perth. The seller, James Kennedy, told the Australian Financial Review that the timing was right to sell the licence because Rolex “may sell directly to shoppers in the future” [1]. An informed seller cashed out of the exact relationship The Hour Glass paid AUD90 million to acquire, and told the press why. That is the central tension of this company, and most of this article is an attempt to work out what it is worth.

The headline valuation looks cheap. Nine-point-four times earnings for a debt-free, record-earning, family-run franchise sounds like a bargain. It is not quite that. Backing out a S$20.3 million non-cash property revaluation that runs through the income statement, recurring earnings are nearer S$162 million, which puts the recurring multiple closer to 10.5 times. That is a fair price, not an obvious bargain. The case for the stock does not rest on the multiple being wrong. It rests on three things the multiple does not capture: a balance sheet with zero financial debt and S$225 million of real estate sitting behind the earnings; the first full year of the THGRAU acquisition, which has not yet been tested across twelve months; and a quiet programme of converting multi-brand stores into single-brand boutiques that improves the mix without showing up as a separate line.

Behind those near-term features sits a slower story the earnings screen cannot see at all. The brief that underwrites this stock is fundamentally defensive: the balance sheet protects the downside, and THGRAU drives the near-term upside. The offensive case is structural and longer-dated. The Hour Glass is not only a Rolex and Patek Philippe distribution machine. It is the Southeast Asian curator of the ultra-premium independent watchmakers that serious collectors graduate into, and it sits in the path of the fastest-growing pool of new wealth in the world. Whether those features are worth paying up for, and how durable the Rolex relationship at the centre of the near-term case really is, is the question the rest of this piece works through.

Read more

On 25 September 2025, a small Singapore-listed dormitory operator did something unusual. It took fourteen of its best-stabilised assets, dropped them into a newly constituted real estate investment trust, and listed that trust on the same exchange where the parent had been trading for two decades. Centurion Accommodation REIT (SGX:8C8U) began trading at S$0.88 a unit. Centurion Corporation Limited (SGX:OU8), the sponsor, retained 42.9% of the new trust, kept full ownership of the trust’s manager, and pocketed approximately S$520 million in cash for the assets it had handed over.

Eight months later, the trust is up. The sponsor’s share price is up. Both are up less than they should be if the market understood what just happened.

The easy version of this story is wrong. The easy version is that Centurion’s share price has rallied from S$0.96 at the start of 2025 to S$1.46 at the 16 May 2026 close, a 52% move, and that the rally exhausted the mispricing. We disagree. The rally was the market crediting Centurion for executing the listing. The market has not yet credited Centurion for what the listing created: a Singapore-listed dormitory operator that now earns three streams of recurring income from one corporate vehicle, owns a directly-held bed count larger than the trust it sponsors, and trades at 1.0x book and 11x trailing earnings as if none of that had changed.

Read more

In October 2025, PropNex Limited (SGX:OYY) traded at S$2.63 [8]. On 19 May 2026 it closed at S$1.83 [8]. Seven months, a 30% drawdown, and the consensus has settled on a clean explanation. New private home launches in Singapore are guided down 17% in 2026. Project marketing commissions are PropNex’s biggest revenue line. The market has done the obvious arithmetic, marked the stock down to a cycle-trough multiple, and moved on.

That arithmetic is incomplete.

There are 13,500 Housing Development Board flats becoming eligible to be sold in 2026. They were bought five years ago at S$400,000 to S$600,000. Their current market value is 30% to 50% higher. The five-year minimum occupation period (the MOP, in Singapore property parlance) is the gate the government places between purchase and resale to deter speculation. When MOP releases, owners gain the legal right to monetise. Most do not sell immediately. But a meaningful share do, and most of those buy something else. The transaction is rarely a single sale; it is a chain. One household decision generates an HDB seller-side commission, a private buyer-side commission, and frequently a rental commission while the private completes. Up to three fee events from a single MOP exit.

This year’s MOP cohort is 69% larger than last year’s. That number — 13,500 versus 8,000 in 2025 — is not a forecast. It is a mechanical consequence of when those flats were completed, which was the 2020 to 2021 COVID-era construction acceleration. The cohort size is therefore set in advance and not subject to forward revision.

PropNex earns from six segments. New launches were 39% of revenue in FY2025. The other 61%, comprising private resale, HDB resale, rental, landed, and commercial, feeds directly off the MOP-driven upgrader chain. Inside the company’s own FY2026 guidance, four of these six segments are flat to up. The one segment that is guided down hard, new launches, is buffered for the first half of 2026 by a S$434 million order book of 4Q25 project marketing sales that has not yet been recognised. Singapore’s developer recognition convention runs three to four months behind option-to-purchase exercise. That revenue is already in the chute.

The stock is being priced as if FY2026 PATMI prints a sharp decline from FY2025’s record S$70.4 million. The supply data, the segment mix, and the recognition lag say something closer to flat. At S$1.83 the equity carries S$0.20 of net cash per share, a 5.2% trailing yield, and a 99.9% payout that survived FY2023’s earnings trough at 92.9%. The peak-cycle thesis assumes management cuts the dividend if earnings fall. The track record says they do not. The 14,333-agent salesforce [11], 1.6 times the size of the next competitor, is a scale advantage that is unlikely to be replicated quickly.

This is the question this long-form deep dive sets out to answer. Is PropNex Limited at S$1.83 a cyclical stock priced for the wrong cycle, or a permanent franchise priced at a fair discount to its peak? The arithmetic, run through every segment from new launches to commercial leasing, says the answer is mostly the former. But the margin of safety is narrower than the headlines suggest, and the flip triggers are sharp enough that this is not a position to take and forget.

Read more

For most of the past decade, Sunright Limited’s share price moved like a SGX small-cap nobody cared about: a few cents either way, divid…

Read more

The company name itself tells part of the story. In Chinese characters, Sheng Siong is written 昇菘, where 昇 (sheng) carries the sense of “to rise” or “to prosper” in Mandarin, and 菘 (siong) is a classical name for the Chinese leafy-green vegetable family that includes bok choy and Chinese cabbage. It is a fitting label for a chain whose founding identity was anchored in fresh produce. Founders Lim Hock Eng, Lim Hock Chee and Lim Hock Leng started the business in 1985, after working in their family’s hog-rearing trade [13], and over forty years built it into a chain whose stated mission has not really shifted: deliver value-for-money daily essentials to heartland families, especially residents of HDB estates, with quality products at competitive prices.

What most people have not done is looked at the company itself as an investment. Sheng Siong Group Ltd. (Singapore Exchange ticker: OV8) is today the third-largest supermarket chain in Singapore, listed on the Singapore Exchange (SGX) Mainboard in August 2011. In its FY2025 financial year ended 31 December 2025, the Group generated S$1.57 billion in revenue and S$149.2 million in net profit, finished the year with S$435.5 million in cash and zero conventional debt, and paid 7.0 cents per share in dividends, a fresh record.

At the share price of roughly S$3.08 in late April 2026, the company carried a market capitalisation of approximately S$4.0 billion [1], placing it just inside Singapore’s mid-cap index neighbourhood. The numbers behind that headline are quietly extraordinary. The story behind those numbers, and whether that story is already fully discounted, is what this article tries to unpack.

Read more

Q&M Dental Group has been listed on the SGX Mainboard since 2009. In that time, it has grown from a small chain into the largest private dental operator in Singapore, survived a pandemic that nearly doubled its PATMI from FY2019 to FY2021, and is now attempting to become a regional dental platform across Asia-Pacific. The question for investors is whether the stock at S$0.60 (up 114% from its 52-week low [1]) reflects the company as it is today, or the company it’s trying to become.

The Company: What Q&M Actually Does

Q&M Dental Group (全民牙科集团) was established around 1996 by Dr Ng Chin Siau — the company describes 2026 as its “30th year.” The name tells the story: “全民” (Quan Min) means “for all the people,” and from day one, Q&M was positioned as mass-market dental care, not premium boutique dentistry. Dr Ng started with a single clinic and built it into Singapore’s dominant private dental chain through relentless acquisition of small practices and organic clinic openings. The corporate entity was incorporated in 2008 and listed on the SGX Mainboard in November 2009.

As at 31 December 2025, the Group operates 110 dental outlets and 5 medical clinics in Singapore, 37 dental clinics in Malaysia, and, through its newly consolidated subsidiary Aoxin Q&M, 7 dental polyclinics and 7 dental hospitals in China, supported by 4 dental laboratories and 2 dental equipment and supplies distribution companies. That’s approximately 161 dental clinic-equivalent outlets across three countries, plus ancillary facilities, served by about 270 dentists seeing roughly 42,000 patient visits per month in Singapore alone.

Beyond clinics, Q&M runs a dental college (the first private postgraduate dental diploma programme in Singapore), a dental AI technology subsidiary (EM2AI), and dental equipment distribution businesses in Singapore and Malaysia.

Revenue is heavily concentrated in Singapore (84% of FY2025 revenue), with Malaysia contributing 6% and China (now consolidated for the first time) adding 9%. This geographic split is about to change dramatically if the company’s acquisition plans materialise.

A Brief History: The Ups and Downs

2009–2016: The Growth Machine. Listed on the SGX in November 2009, Q&M expanded aggressively through clinic acquisitions. Revenue grew from roughly S$60 million to S$155 million. A valuable stake in Aidite Technology (a Chinese dental supplies manufacturer) generated significant associate income, and FY2016 PATMI hit S$28.3 million, though much of it came from one-off disposal gains.

2017–2019: Restructuring. Q&M spun off its China operations as Aoxin Q&M, disposed of its Aidite stake, and repaid its first S$60 million Medium Term Note. Stripping out one-offs, core dental profit was roughly S$13 million per year. Revenue grew modestly to S$128 million by FY2019.

2020–2021: The COVID Windfall. Q&M pivoted into COVID-19 PCR testing, boosting medical lab segment revenue from near-zero to S$45.4 million. Total revenue hit S$205.6 million, PATMI reached S$30.5 million, and the company paid S$0.04/share in dividends. This was the peak. The testing revenue was ephemeral.

2022–2023: The Hangover. Testing revenue evaporated, PATMI fell to S$11.3–11.5 million as lab impairments and Aoxin losses dragged on results. But the core dental business proved its resilience: core healthcare EBITDA was stable at S$37–40 million throughout.

2024–2025: The M&A Pivot. Core dental profit recovered to S$26.1 million (FY2024, restated) and then S$30.4 million (FY2025) — a 16% year-on-year jump. Meanwhile, Q&M consolidated Aoxin Q&M as a subsidiary, raised S$130 million through Medium Term Notes at 3.95%, and signed non-binding MOUs to acquire dental groups in Australia (AUD 144.5M), Thailand (30+ clinics), and China. Reported PATMI fell to S$9.3 million due to one-off consolidation losses and MTN interest costs — but the core business has never been stronger.

Financial Performance: What the Numbers Tell Us

The most important insight from the financials is that Q&M’s core dental business has been remarkably stable and quietly growing, even as the headline numbers have been volatile.

Revenue. Core dental revenue has grown at a roughly 5% CAGR over the past five years, from S$126 million in FY2020 to S$195 million in FY2025. The jump in FY2025 includes approximately S$18 million from the Aoxin consolidation. Stripping that out, organic core dental revenue growth was still solid at approximately 3–4%.

Profitability. The reported PATMI line is noisy, distorted by COVID testing profits in FY2020–21, lab impairments in FY2022–23, and consolidation losses in FY2025. The cleaner metric is core dental profit after tax, which has grown from S$17.1 million in FY2022 to S$30.4 million in FY2025, a 78% increase over three years. This is the trend that matters.

Margins. Core dental segment results (before corporate costs and finance charges) were S$55.4 million on S$195 million revenue in FY2025, implying a segment margin of roughly 28%. Employee costs are the largest expense at S$115 million (58% of revenue), followed by lease-related depreciation at S$13.8 million (7%).

Cash Flow. Operating cash flow has been consistently strong: S$33–50 million annually. FY2025 saw S$36.7 million, sufficient to cover capex of S$4.8 million and dividend payments. The S$130 million MTN issuance in July 2025 transformed the cash position from S$34 million to S$117 million.

Balance Sheet: From Conservative to Leveraged

The balance sheet has undergone a significant shift. Prior to FY2025, Q&M maintained a relatively conservative balance sheet with net debt of S$39–46 million and a debt-to-equity ratio of 0.68–0.83x. The S$130 million MTN issuance changed this materially.

As at 31 December 2025, total borrowings (including finance leases) stood at S$143.4 million against cash of S$117.1 million, giving a net debt of just S$26.3 million. However, this is somewhat misleading: the cash is earmarked for acquisitions. If the Australian deal (AUD 144.5M ≈ S$130M) closes, the cash will be substantially deployed, and net debt could rise to S$100M+ depending on the financing mix.

Goodwill increased from S$52.4 million to S$75.2 million following the Aoxin consolidation. This will grow further if the M&A pipeline closes. NAV per share is S$0.1105 (equity attributable to owners of the parent divided by shares outstanding), meaning the stock trades at approximately 5.4x book value on a per-share basis.

The Clinic Network: Scale as Moat

Q&M’s network of 110 dental outlets in Singapore represents the single largest private dental chain on the island. For context, Singapore has approximately 1,400 licensed dental clinics [8]; Q&M operates roughly 8% of them. The next largest chain is significantly smaller.

This scale provides several advantages. First, it gives Q&M bargaining power with landlords and suppliers. Second, it enables a training and talent pipeline through the Q&M College, where the company can recruit, train, and rotate dentists across its network, which is difficult for smaller players to replicate. Third, the CHAS (Community Health Assist Scheme) subsidy framework favours larger chains that can absorb the administrative burden of subsidy claims and fee benchmark compliance.

The enhanced CHAS subsidies effective from October 2025, covering additional restorative procedures and expanding coverage to 1.7 million cardholders [6], are a structural tailwind. Q&M’s clinics are CHAS-accredited, and management noted a roughly 3% revenue boost from the subsidy enhancements in H2 2025. The upcoming Flexi-MediSave expansion (mid-2026) allowing seniors to use S$400/year for dental work at CHAS clinics should provide further support [6].

The Johor-Singapore Special Economic Zone: Threat and Opportunity

The most disruptive near-term development for Singapore’s dental market may not come from competitors or regulation. It may come from infrastructure. The Johor Bahru–Singapore Rapid Transit System (RTS) Link, scheduled to open in December 2026, will connect Bukit Chagar in Johor to Woodlands North in Singapore with a design capacity of 10,000 passengers per hour [11]. Combined with the broader Johor-Singapore Special Economic Zone (JS-SEZ) framework, this creates a step-change in cross-border accessibility.

The implications for dental care are significant. Routine dental procedures in Johor cost 40–70% less than in Singapore. A scaling and polishing that costs S$100–180 in a Singapore private clinic runs RM80–150 (S$25–45) across the Causeway. With the RTS Link reducing crossing time to minutes rather than the current hour-plus queue at the land checkpoints, the calculus for price-sensitive Singaporean patients shifts dramatically. This is particularly relevant for elective and cosmetic procedures — crowns, veneers, implants, where the price differential runs into thousands of dollars.

Q&M is uniquely positioned on both sides of this equation. It operates 37 clinics across Malaysia — with locations in Kuala Lumpur, Selangor, Negeri Sembilan, Malacca, and Johor, more than any other Singapore-listed dental chain. If patient flow moves south, Q&M captures some of that demand in its Malaysian clinics rather than losing it entirely. However, the risk to Singapore same-store revenue is real: Q&M’s 110 Singapore outlets generate 84% of group revenue, and any meaningful patient outflow would hit the highest-margin part of the business.

Management has acknowledged the JS-SEZ in the AR2025 Operations Review, noting that Q&M continues “to explore opportunities to grow our dental business, particularly within the Johor–Singapore Special Economic Zone, with the upcoming Rapid Transit System expected to enhance connectivity and support growth in Johor.” Notably, management frames the RTS Link as a growth opportunity for its Malaysian clinics rather than a cannibalization risk to Singapore — investors should weigh whether this framing adequately addresses the downside scenario. H2 2026 same-store revenue trends will be the first real data point once the RTS Link comes online.

Singapore’s Demographic Tailwind: Ageing by the Numbers

While the JS-SEZ creates near-term uncertainty, Singapore’s demographic trajectory is an unambiguous structural tailwind for dental care demand. By 2030, 24% of Singapore’s resident population will be aged 65 or older, up from 18.4% in 2023 [5]. This is one of the fastest ageing populations in the world.

The dental implications are acute. Among Singaporeans aged 65 and above, approximately 69% wear dentures and dental disease prevalence is significantly higher than in younger cohorts [7]. Periodontal disease, tooth loss, and the need for prosthetic and restorative work all increase sharply with age. The Ministry of Health’s expansion of CHAS subsidies and the Flexi-MediSave dental benefit are direct policy responses to this demographic reality [6].

For Q&M, this means the addressable patient base for its highest-frequency services (dentures, crowns, extractions, periodontal treatment) is growing structurally, and government subsidies are reducing the out-of-pocket barrier. The company’s HDB heartland clinic locations are precisely where Singapore’s elderly population is concentrated.

The M&A Bet: Going Regional

The most significant strategic shift in Q&M’s 30-year history is happening right now. The company has simultaneously announced three major international expansion initiatives:

Australia (AUD 144.5 million). In March 2026, Q&M signed a non-binding MOU to acquire a leading Australian dental group operating 40+ clinics across NSW, VIC, QLD, TAS, and ACT with approximately 120 dentists. The purchase includes a profit guarantee of 5–8 years. To understand the significance of this deal, consider the market Q&M is entering: Australia’s dental industry is worth approximately A$13 billion annually and growing at roughly 3% per year [10], with no single dominant national chain. The market has been undergoing PE-driven consolidation — 1300 Smiles was acquired by BUPA in 2021, Abano Healthcare (NZ-listed, with Australian operations) was taken private by Adams & Co, and several mid-tier chains have attracted private equity interest. Q&M is entering this consolidation wave as a listed strategic buyer with a dental operating playbook, which differentiates it from pure financial buyers. The AUD 144.5 million price tag, however, makes this Q&M’s largest-ever acquisition by a wide margin and represents a market-entry bet where the company has zero operating history.

Thailand (30+ clinics). In October 2025, Q&M signed a non-binding MOU to acquire a Thai dental group focused on cosmetic and aesthetic dentistry, also with a profit guarantee.

China (via Aoxin Q&M). With Aoxin now a subsidiary, Q&M is deploying capital through it to acquire dental chains in China beyond Aoxin’s existing northeastern base. Two MOUs have been signed totalling approximately RMB 420 million (S$77M), targeting clinics in southern China.

The strategy is a “partnership-driven acquisition model” where founders receive a mix of cash and Q&M equity, aligning incentives. If all three deals close, Q&M could grow from approximately 161 dental outlets to potentially 300+ within two years, with a medium-term target of 300–400 clinics.

The risk is obvious: three major cross-border acquisitions simultaneously, funded partly by debt, in markets the company has limited experience operating in (Australia and Thailand are entirely new). Integration risk, currency risk, and execution risk are all elevated. This is what makes Q&M a coin flip: the upside from successful execution is transformative, but the company is attempting it all at once with no margin for error.

Competitive Advantages and Their Durability

Q&M’s moat rests on four pillars.

Network density in Singapore. With 110 outlets, Q&M has the largest private dental footprint. This is difficult to replicate because good clinic locations (typically in HDB heartlands and shopping centres) are scarce, and the company has 30 years of landlord relationships. Durability: strong in Singapore, not yet established regionally.

Talent pipeline and the dentist shortage. The Q&M College of Dentistry, now EduTrust-certified for four years, provides a training advantage. The company employs 270 dentists and can offer them a career progression path across its network. This matters more than it might appear: Singapore faces a genuine supply constraint in dental professionals. The country’s only domestic dental school (NUS Faculty of Dentistry) graduates approximately 50–60 dentists per year [9], and foreign-trained dentists must pass a rigorous licensing examination. The total number of registered dentists in Singapore is roughly 2,600 [8], serving a population of 5.9 million. This supply bottleneck is Q&M’s single biggest constraint on organic growth (you cannot open new clinics without dentists), but it is simultaneously a structural moat: any competitor looking to build a rival chain faces the same limited talent pool and the same multi-year lead time to train and credential new practitioners. Durability: strong — the licensing regime and limited training capacity are structural, not easily disrupted.

CHAS accreditation and government relationships. As the largest CHAS-accredited dental chain, Q&M benefits disproportionately from subsidy enhancements. The upcoming requirement for non-accredited clinics to be offboarded by December 2026 further entrenches incumbents [6]. Durability: strong, but dependent on government policy.

Founder leadership. Dr Ng Chin Siau controls approximately 56% of shares through Quan Min Holdings and has been CEO since founding the company. This provides strategic continuity but creates key-man risk. Durability: inherently fragile.

Valuation: What You Pay vs. What You Get

Q&M’s valuation is complicated by the noisy earnings picture. The metric that matters most here is the normalised P/E, because reported earnings are so distorted by one-offs that trailing multiples are meaningless, and EV/EBITDA doesn’t capture the finance cost burden from the new S$130 million debt.

Trailing P/E: 61x [1]. This is based on FY2025 reported PATMI of S$9.3 million, which is distorted by a S$4.2 million loss on the deemed disposal and consolidation of Aoxin Q&M and EM2AI, S$2.4 million MTN interest, and PSP-related expenses. This is not a meaningful number.

Normalised P/E: 22–27x. Using adjusted PATMI of S$17 million (excluding one-offs), the P/E is approximately 33x. Using core dental profit of S$30.4 million and attributing it more generously, the multiple drops further. Morningstar calculates a normalised P/E of 22.4x [2].

EV/EBITDA: 15.9x [1]. EBITDA was S$37.8 million in FY2025. At an enterprise value of S$671 million [1], this is roughly in line with IHH Healthcare but significantly above Raffles Medical.

P/B: 5.4x — NAV per share is S$0.1105 (based on equity attributable to parent of S$104.4 million divided by approximately 947 million shares). At S$0.60, the stock trades at a substantial premium to book. Third-party data providers report P/B ratios in the range of 4.2–5.4x depending on whether total equity (including minority interests) or parent-only equity is used. Either way, the premium reflects the market’s view that Q&M’s intangible assets (brand, network, relationships) are worth significantly more than their accounting value.

Dividend Yield: 1.4% [2]. At S$0.0082 per share, the yield is modest. However, management has historically been flexible with dividends, paying 4 cents in FY2021 (7% yield at the time) and as low as 0.69 cents in FY2023.

Relationship with Aoxin Q&M (SGX: 1D4). Aoxin’s market cap is just S$26 million [3] despite operating 24 facilities in China. Q&M’s 52.65% stake is worth roughly S$13.5 million at market, a tiny fraction of Q&M’s S$568 million market cap [1]. If Aoxin’s China expansion succeeds, there could be significant value embedded in this subsidiary. If it fails, the write-downs would be manageable relative to Q&M’s overall business.

Dividend History: Feast and Famine

Q&M’s dividend track record is lumpy. During the COVID windfall years (FY2020–21), the company paid out S$0.03 and S$0.04 per share, extraordinary payouts funded by extraordinary testing profits. Since then, dividends have normalised to S$0.0069–S$0.011 per share, with payout ratios of 57–83%.

In FY2025, the payout ratio was 83% of reported earnings but only about 46% of core dental profit, suggesting the current S$0.0082 per share dividend is sustainable even without M&A-driven earnings growth.

For yield-focused investors, Q&M is not the right vehicle at current prices. The 1.4% yield is below the SGX healthcare average. The investment case here is about capital appreciation from the M&A-driven growth thesis, not income.

Key Growth Drivers (2026–2030)

1. Australian dental market entry. If the AUD 144.5M acquisition closes, Q&M immediately gains scale in a large, fragmented, and high-margin developed market. Australia’s dental industry is approximately A$13 billion [10], with no single dominant chain. The profit guarantee de-risks the near-term earnings impact.

2. Enhanced CHAS subsidies and Flexi-MediSave. The expansion of government dental subsidies is a multi-year tailwind for Singapore revenue. Q&M is the largest beneficiary by virtue of its network size. The Flexi-MediSave expansion in mid-2026 will further boost demand at CHAS clinics.

3. China expansion via Aoxin. Aoxin’s move into southern China through acquisitions diversifies away from its northeastern base. China’s dental market is growing rapidly. Private dental chains are consolidating in Tier 1–2 cities, and Q&M has a platform to participate.

4. Thailand entry. Cosmetic and aesthetic dentistry in Thailand is a growing niche, driven by both domestic demand and medical tourism. The 30-clinic acquisition would provide immediate market presence.

5. Technology and EM2AI. Q&M’s investment in dental technology through its subsidiary EM2AI deserves more attention than it typically receives. EM2AI is developing AI-assisted dental imaging and treatment planning tools — essentially using machine learning to analyse dental X-rays, detect pathologies, and recommend treatment options. The technology is still in its early commercial stages, and Q&M has not disclosed standalone revenue or profitability for EM2AI. What is clear from the annual reports is that EM2AI is being positioned as both an internal efficiency tool (improving diagnostic speed and consistency across 270 dentists) and a potential external licensing play. If the technology proves clinically robust, it could be deployed across the entire expanded clinic network post-acquisition — creating operating leverage that is distinct from simply adding more clinics. For now, EM2AI remains more of an R&D cost centre than an earnings contributor, but it is the kind of optionality that could differentiate Q&M from pure brick-and-mortar dental chains in 3–5 years.

Macro Environment: Headwinds the Market Isn’t Discussing

No analysis of Q&M is complete without acknowledging the macro backdrop. The US–China trade war has intensified through 2025–2026, with US tariffs of 10–26% now applied across ASEAN imports. Singapore’s Ministry of Trade and Industry (MTI) has upgraded its 2026 GDP growth forecast to 2.0–4.0% [4], after the economy expanded 5.0% in 2025, and business confidence surveys show softening consumer sentiment.

Dental care occupies an unusual position in a downturn. Basic dental services (check-ups, fillings, extractions) are relatively recession-resilient; toothache doesn’t wait for an economic recovery. However, elective and cosmetic procedures (orthodontics, veneers, implants, whitening) are highly deferrable and carry the highest margins. If consumer confidence weakens, these procedures are among the first discretionary healthcare expenses to be postponed. Q&M does not break out its revenue between basic and elective procedures, which makes it difficult to model the sensitivity. As a rough guide, dental industry surveys suggest that elective and cosmetic work typically accounts for 25–35% of private dental revenue in developed Asian markets (an estimate, not a verified Q&M-specific figure).

The tariff environment [12] also creates indirect risk for Q&M’s China operations. Aoxin Q&M’s patient base in northeastern China is concentrated in provinces with heavy manufacturing exposure. A trade-war-induced slowdown in Chinese industrial activity could depress dental demand in precisely the regions where Aoxin operates.

More broadly, if Singapore's growth disappoints the upgraded forecast — not the base case, but tariff uncertainty makes it possible — Q&M’s fixed-cost base (clinic leases, salaried dentists, equipment depreciation) means operating leverage works in reverse. A 5–10% decline in same-store revenue would flow through to a disproportionately larger decline in operating profit, given that employee costs alone account for 58% of revenue. The company — listed in November 2009, after the Global Financial Crisis — has never stress-tested its clinic economics through a genuine consumer recession as a public company. COVID was a supply-side demand shock with a massive government spending offset, not a consumer spending contraction.

Major Risks and Bear Case

Execution risk on concurrent M&A. Three major cross-border acquisitions simultaneously is ambitious for a company of Q&M’s size. Each market has different regulatory, cultural, and operational challenges. The management team’s experience is overwhelmingly in Singapore and Malaysia.

Leverage risk. The S$130 million MTN at 3.95% adds approximately S$5.1 million in annual interest expense. If the Australian deal is partly debt-funded, leverage could increase further. In a rising-rate environment, this is a drag on earnings.

Key-man risk. Dr Ng Chin Siau is the founder, CEO, and controlling shareholder. The company’s strategic direction, acquisition strategy, and talent relationships are heavily concentrated in one individual. There is no disclosed succession plan.

Integration risk. Dental practices are relationship-driven businesses. When you acquire a clinic, the dentist might leave, and take the patients with them. Profit guarantees provide protection but only for 5–8 years.

Aoxin Q&M drag. The China operations through Aoxin have been loss-making at the associate level for several years. Now that Aoxin is consolidated, these losses flow through Q&M’s P&L. If the China expansion fails, impairment charges could be significant (goodwill from Aoxin is already S$22+ million).

Currency and interest rate risk. Q&M’s regional expansion introduces multi-currency exposure that the company has not historically managed. Revenue will soon be earned in SGD, MYR, RMB, and AUD — each with different drivers and volatility profiles. The Australian dollar has weakened against the SGD in recent quarters, meaning AUD-denominated earnings will translate into fewer Singapore dollars. The RMB faces structural pressure from the US–China trade war [12]. On the financing side, the S$130 million MTN at 3.95% fixed rate is well-structured, but any additional debt to fund the Australian acquisition may carry a higher coupon in the current rate environment. Total finance costs rose from S$5.4 million in FY2024 to S$6.4 million in FY2025 — and will rise further if the M&A pipeline is partly debt-funded.

Regulatory risk. Changes to CHAS subsidies, dental licensing regulations, or foreign ownership rules in target markets could impact growth plans.

Management Quality and Capital Allocation

Dr Ng Chin Siau has led Q&M from one clinic to over 160 dental outlets over 30 years, an impressive track record of organic and acquisitive growth. The management team is small and lean, with CFO Ng Sook Hwa (since 2002, CFO since 2022) and COO Dr Ang Ee Peng Raymond providing continuity.

The board has been strengthened with the appointment of independent chairman Ted Tan (former Deputy CEO of Enterprise Singapore) and Professor Chew Chong Yin (former Dean, NUS Faculty of Dentistry). These appointments bring M&A expertise and dental industry credibility.

Capital allocation has been mixed. The COVID-era dividends (S$0.04/share declared for FY2021) were generous. Cash dividends paid to equity owners totalled S$48.8 million during calendar year 2021 (this figure includes both FY2020 final dividends and FY2021 interim dividends paid during that year), a level of distribution that proved unsustainable as testing profits evaporated. Share buybacks have been more disciplined, with the company repurchasing shares at prices below current levels.

The S$130 million MTN issuance was well-timed (3.95% fixed rate), and the recent allocation of up to 90 million shares for buyback provides flexibility.

Insider buying by Quan Min Holdings (Dr Ng’s vehicle) in April 2026, totalling approximately S$4.6 million, is a positive signal.

One underappreciated aspect of Q&M’s corporate profile is its community dental programme. The company operates a free dental clinic providing pro bono dental care to low-income patients, one of very few listed healthcare companies in Singapore to run a sustained charitable healthcare service rather than writing a cheque to a foundation. For ESG-focused investors increasingly screening healthcare companies on social impact metrics, this is a tangible differentiator. It also speaks to the company’s social licence to operate as the largest private dental chain in a market where dental care affordability is a growing policy concern.

Who Owns Q&M: The Shareholder Register

Understanding who owns Q&M is critical to understanding how this stock trades, and what happens if things go wrong.

As at 1 April 2026, the top 20 registered shareholders hold 82.6% of shares outstanding [14]. Only 33.9% of issued shares are in public hands. The register is dominated by three distinct groups:

The Founder Block (55.8%). Dr Ng Chin Siau’s control over Q&M flows primarily through Quan Min Holdings Pte Ltd, which holds 528.3 million shares — 236.7 million registered under its own name (25.0%) and 291.6 million held via various nominees (30.8%), totalling 55.79% of shares outstanding [14]. Dr Ng holds 49.80% of Quan Min Holdings directly and is deemed interested in a further 121,200 shares held by his spouse, giving him a total deemed interest of 55.80% [14]. He also holds 6.6 million shares (0.70%) in his own name. Two other entities with the Quan Min name — Quan Min Plus (1.82%) and Quan Min Plus 2 (0.79%) — appear in the top 20 register, but the AR2025 does not list them as giving Dr Ng any deemed interest; their beneficial ownership is not disclosed [14]. Taking only the disclosed interests, Dr Ng’s effective voting power is approximately 56.5% — an outright majority. He can pass or block any ordinary resolution unilaterally. For investors, this means governance is effectively a one-man show: whatever Dr Ng wants to do, including the current triple-acquisition strategy, will happen unless it requires a supermajority vote. The recent April 2026 purchases by Quan Min Holdings (approximately S$4.6 million in open-market buying) reinforce that the founder is putting personal capital behind the M&A thesis at current prices.

The Tsao Family / OCTAVE Block (6.8%). IMC Dynamic Investments holds 64.1 million shares (6.77%), making it the only other substantial shareholder besides Dr Ng [14]. IMC Dynamic is wholly owned by IMC Heritas Investments, which is in turn wholly owned by Tsao Pao Chee Group [14], a multi-generational Singaporean family conglomerate (the family describes itself as fourth-generation [15]) with interests spanning shipping, real estate, and healthcare-focused impact investing through its OCTAVE Capital arm. This is not a passive index fund parking capital. It is a strategic family office with a stated focus on healthcare investments across Asia [15]. Their presence at 6.8% as at April 2026 suggests alignment with Q&M’s regional healthcare expansion thesis. SGX substantial shareholder disclosure rules require notification when crossing the 5% threshold, so we know IMC Dynamic has remained above 5% continuously — but movements within that band are not publicly disclosed, and we cannot confirm the exact size of their position at any earlier point.

Nominee, Brokerage, and Individual Accounts. The remaining top 20 shareholders fall into two categories. The first is custodian and brokerage accounts — OCBC Securities (8.7%), Raffles Nominees (8.6%), Phillip Securities (7.2%), KGI Securities (6.5%), Sing Investments & Finance Nominees (5.0%), DBS Nominees (3.8%), and several smaller custodians including Citibank, HSBC, Maybank, UOB, Moomoo, and iFAST nominees [14]. These accounts collectively hold a large share of the register, but without beneficial ownership disclosure it is impossible to determine how much of this block is institutional versus high-net-worth retail. No single institutional fund has disclosed a substantial (5%+) position in Q&M. Among US-registered funds, SEC filings show Dimensional Fund Advisors (DFA) holding Q&M through its small-cap international index funds [16] — a passive, systematic allocation rather than a conviction bet. Non-US institutional holders would not appear in SEC filings and could hold positions through the nominee accounts above. The second category is named individuals: Chan Pui Kee (1.55%) and Lai Ming Chun (1.38%) are the largest individual holders outside the Ng family [14]. Their relationship to the company, if any, is not disclosed in the AR2025.

What This Means for the Investment Thesis. The shareholder structure has three important implications.

First, liquidity is thin. With approximately 56% locked up by the founder and 6.8% by a strategic family office, only about a third of shares trade freely. This amplifies price moves in both directions, partly explaining the 114% rally from the 52-week low. It also means any attempt to build or exit a meaningful position will move the price.

Second, institutional underownership is both a risk and an opportunity. Third-party ownership analyses estimate institutional ownership at less than 5% [16], meaning Q&M lacks the analyst coverage and fund flows that typically support valuation re-ratings. However, if the M&A strategy executes well and the company’s market cap grows into the S$800M–1B range, it could cross the threshold for inclusion in more small-cap indices and attract passive fund inflows — a catalyst that is entirely absent today.

Third, minority shareholder protection is a legitimate concern. With 55.8% control through Quan Min Holdings alone, Dr Ng has the votes to approve related-party transactions, share issuances, and strategic pivots without minority consent. The partnership-driven acquisition model — where founders of acquired businesses receive Q&M equity — means dilution is a structural feature of the growth strategy, not a one-off event. The board’s independent directors (Ted Tan, Prof Chew Chong Yin) provide some governance guardrails, but the power asymmetry is stark. Investors buying at S$0.60 are essentially betting on Dr Ng’s judgment and integrity with limited structural protections beyond SGX listing rules. The coin flip, ultimately, lands on one man’s ability to execute.

Bull vs Bear Investment Thesis

The Bull Case

Q&M is at an inflection point. The core Singapore dental business is growing steadily, generating S$30+ million in annual profit with strong operating cash flow. The enhanced CHAS subsidies provide a structural tailwind. The S$130 million war chest enables transformative M&A. If the Australian, Thai, and Chinese acquisitions all close with profit guarantees, FY2027–28 earnings could step-change higher. The profit guarantees alone suggest EPS could more than double from FY2025 levels. The stock trades at a normalised P/E of 22–27x, which is reasonable for a healthcare company with multi-year growth visibility. The founder’s 56% stake and recent insider buying provide alignment. Illustrative scenario (not a price target): S$0.65–0.75, implying 10–25% upside from S$0.60.

The Bear Case

The stock has already run 114% from its 52-week low [1], and much of the M&A optionality is priced in. Three concurrent cross-border acquisitions by a management team with limited international experience is high-risk. The S$143 million in debt creates earnings drag through S$6.4 million in annual finance costs. Aoxin Q&M has been a persistent drag on earnings and is now fully consolidated. If any major deal falls through or integration stumbles, the stock could de-rate quickly. The trailing P/E of 61x leaves no margin for disappointment. Key-man risk is unmitigated.

Consider a simple stress scenario: if a macro downturn drives a 5–10% decline in same-store revenue across Singapore — not implausible if the JS-SEZ diverts patients to Johor while a tariff-induced slowdown dampens elective procedure demand — the impact on profitability is amplified by Q&M’s fixed-cost structure. Employee costs (S$115 million) and lease depreciation (S$13.8 million) are largely fixed in the near term. A 7% revenue decline (roughly S$14 million) would fall almost entirely to the bottom line, potentially halving core dental operating profit. The company has never been tested through a genuine consumer recession as a listed entity — and it would enter one at higher leverage than at any previous point in its history.

Illustrative scenario (not a price target): S$0.40–0.50, implying 15–33% downside from S$0.60.

What Could Break the Thesis

For bulls: If the Australian deal falls through (it’s a non-binding MOU), the growth narrative collapses. If integration of Aoxin leads to sustained losses that offset Singapore profits, the quality of the business deteriorates. A sharp deterioration in Singapore dental demand (recession, regulatory change) would undermine the base business.

For bears: If all three acquisitions close on favourable terms with strong profit guarantees, the earnings step-change could be dramatic enough to justify current valuations. A re-rating to peer multiples (IHH at 37x, Raffles at 20x) on higher earnings would drive significant upside.

The Bottom Line

At S$0.60, you are not buying a dental business. You are underwriting one man’s ability to simultaneously execute three cross-border acquisitions — in Australia, Thailand, and China — while managing S$143 million in debt, a thin public float, and a core Singapore business that has never been tested through a consumer recession.

The data says the core business deserves its premium: 5–7% revenue growth, 28% segment margins, S$35–40 million in annual operating cash flow, and a founder with 30 years of compounding behind him. But it also says Q&M has zero operating history in any of its target markets, and the entire M&A pipeline rests on non-binding MOUs.

That’s the coin flip. The fundamentals are real. The ambition is extraordinary. And the gap between the two is where the risk lives.

References

Market Data Sources

1. Stock Analysis (stockanalysis.com) — Q&M share price (S$0.60), market cap (S$568M), trailing P/E (61x), EV/EBITDA (15.94x), enterprise value (S$671M), shares outstanding (~947M), 52-week low (S$0.245–0.25), 52-week price change (+114%). Data as at 20 April 2026.

2. Morningstar — Normalised P/E (22.42x), dividend yield range (1.37–2.12%). Accessed April 2026.

3. Yahoo Finance / MarketScreener — Aoxin Q&M (SGX: 1D4) share price (S$0.194), market cap (~S$25.6M). Accessed April 2026.

Industry and Macro Data Sources

4. Singapore Ministry of Trade and Industry (MTI) — 2026 GDP growth forecast upgraded to 2.0–4.0%; 2025 full-year GDP growth of 5.0%. MTI press release, 10 February 2026. https://www.mti.gov.sg/newsroom/mti-upgrades-2026-gdp-growth-forecast-to--2-0-to-4-0-per-cent-/

5. National Population and Talent Division, Singapore — Population projections: 24% of residents aged 65+ by 2030, up from 18.4% in 2023. https://www.population.gov.sg/our-population/population-trends/longevity/

6. Ministry of Health, Singapore / CHAS.sg — Enhanced CHAS dental subsidies effective 1 October 2025; Flexi-MediSave expansion for seniors (S$400/year) effective mid-2026; non-accredited clinic offboarding by 31 December 2026; 1.7 million CHAS cardholders. https://www.moh.gov.sg/newsroom/enhanced-financing-support-for-chas-dental-procedures-and-financial-governance-of-chas-clinics/

7. MOH Singapore — Oral health survey data: approximately 69% denture prevalence among Singaporeans aged 65+. (Note: exact survey year varies by source; figure is from publicly available MOH oral health statistics.) https://www.ndcs.com.sg/news/patient-care/closing-the-gap-in-elderly-oral-healthcare-in-singapore-with-smartrpd

8. Singapore Dental Council (SDC) — Approximate number of registered dentists in Singapore (~2,600). Registry data accessed via public sources. https://data.gov.sg/datasets/d_6c8cf7ce0c6830608637418fcd0979a7/view

9. NUS Faculty of Dentistry — Approximate annual graduate output of 50–60 dentists. Based on publicly available faculty information. https://sgschoolkaki.com/statistics/university-graduates/dentistry

10. IBISWorld — Australian dental services industry: approximately A$13 billion market size, ~3% annual growth. Industry report data. https://www.aihw.gov.au/reports/dental-oral-health/oral-health-and-dental-care-in-australia/contents/costs

11. JB-SG RTS Link project authority — RTS Link design capacity of 10,000 passengers per hour; scheduled opening December 2026; connecting Bukit Chagar (Johor) to Woodlands North (Singapore). https://www.lta.gov.sg/content/ltagov/en/upcoming_projects/rail_expansion/JB-Singapore_RTS_link.html

12. US Trade Representative / Singapore government sources — US tariffs of 10–26% on ASEAN goods, referenced in the context of the 2025–2026 trade environment. https://www.aseanbriefing.com/news/u-s-tariffs-in-asia-2025-a-regional-investment-map/

13. Ken Research — Singapore dental services market revenue estimate (~USD 2.4 billion in 2026). https://www.kenresearch.com/industry-reports/singapore-dental-services-market

14. Q&M Dental Group — Statistics of Shareholdings as at 1 April 2026 (AR2025, pp.128–129). Source of: top 20 registered shareholders, substantial shareholders list, public float (33.93%), Quan Min Holdings total stake (55.79% including nominees), Dr Ng Chin Siau’s deemed interest (55.80%), IMC Dynamic Investments (6.77%), Tsao Pao Chee Group corporate chain, Quan Min Plus (1.82%), Quan Min Plus 2 (0.79%), and named individual shareholders.

15. Tsao Pao Chee Group / OCTAVE Capital — corporate website (tsaopaochee.com) and OCTAVE Capital website (octavecapital.co). Source of: Tsao family generational history (”fourth-generation”), OCTAVE Capital’s healthcare investment focus across Asia, and IMC Group corporate structure.

16. Fintel / Simply Wall St / Yahoo Finance — Institutional ownership estimates for Q&M Dental (<5% institutional), Dimensional Fund Advisors (DFA) holdings via small-cap international index funds. Accessed April 2026. Note: these are third-party estimates based on disclosed filings; actual institutional ownership may differ as non-US funds and nominee-held positions are not fully captured.

Notes on Data Integrity

• FY2024 figures throughout this article use the restated numbers as reported in the FY2025 filing (Note 18), which differ from the originally published FY2024 figures. Where relevant, this is noted in the text.

• Dental price comparisons between Singapore and Johor (scaling: S$100–180 vs RM80–150) are indicative ranges based on publicly available clinic fee schedules and are not sourced from a single authoritative database.

• The estimate that elective/cosmetic work accounts for 25–35% of private dental revenue is an industry-level approximation, not a Q&M-specific disclosure.

• Bull and bear illustrative scenarios are editorial in nature and are not derived from a formal discounted cash flow or earnings model.

All financial data sourced from Q&M Dental Group SGX filings (FY2015–FY2025) and Annual Reports. Market data as at 20 April 2026.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Q & M Dental Group (Singapore) Limited’ SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

And yet, at a trailing P/E of 7.2x and a market cap of just S$215 million, the stock trades as if none of this matters.

This piece is a deep dive into Hafary: its history, business model, financials, competitive advantages, and the strategic pivot that could change the investment case entirely.

A Brief History: From Tile Trader to Integrated Platform

Hafary was founded in 1980 by Low Kok Ann, who started as a small tile trader in Singapore. The business grew steadily through the construction booms of the 1990s and 2000s, eventually listing on the SGX Catalist board in 2010.

For most of its history, Hafary operated a simple but effective model: source tiles and surfacing materials from Europe (mainly Italy and Spain) and Asia, then distribute them through showrooms to retail customers and through project teams to developers and contractors. Two segments, General (retail) and Project (developers), accounted for virtually all revenue.

The company weathered several downturns. Revenue peaked at S$120 million in FY2018 before declining through FY2019–2020, hit by a softening construction cycle and then the COVID-19 circuit breaker, which shut showrooms and halted construction sites for months. FY2020 was the trough: revenue fell 22% to S$84 million, and PATMI dropped 48% to S$5.3 million.

What happened next was remarkable. From that FY2020 low, Hafary’s revenue has grown more than threefold to S$287 million in FY2025. The recovery was driven by three forces: a rebound in Singapore’s construction and renovation activity, geographic expansion into Malaysia and export markets, and, most importantly, the launch of a manufacturing segment that did not exist before FY2023.

Business Model: Three Segments, One Ecosystem

Hafary today operates across three segments.

General (49.7% of FY2025 revenue, S$142.7M): This is the retail-facing arm. Homeowners, interior designers, architects, and renovation contractors purchase tiles, natural stone, wood flooring, countertops, and sanitary ware from Hafary’s showrooms. The company operates multiple showrooms in Singapore (including the flagship Hafary House at 161 Lavender Street) and one in Petaling Jaya, Malaysia. This segment has been the steady base of the business for decades.

Project (28.3%, S$81.2M): Hafary supplies surfacing materials for public sector projects (HDB flats, government buildings, hospitals) and private developments (condominiums, commercial buildings, hotels). Customers include architecture firms, property developers, and construction companies. This segment is more lumpy and contract-driven, but benefits from long-term government infrastructure spending.

Manufacturing (22.0%, S$63.1M): This is the newest and fastest-growing segment. Since commencing ceramic tile production at two facilities in Kluang, Johor in June 2023, manufacturing revenue has surged from S$5.4 million in FY2023 to S$46.5 million in FY2024 and S$63.1 million in FY2025 (a 35.6% year-on-year increase). The segment serves Malaysian and international markets, with the US emerging as a significant export destination (S$35.7 million in FY2025 revenue).

Geographic exposure has diversified meaningfully. Singapore remains the anchor market at S$171.4 million (59.7% of revenue), but Malaysia contributes S$54.5 million (19.0%), the US S$35.7 million (12.4%), and the remaining 8.9% (S$25.5 million) is spread across 12 other countries.

A broader international footprint than the headline numbers suggest. What the geographic revenue table does not fully convey is the network of dedicated entities Hafary has seeded across Asia. In China, the group operates through three distinct vehicles: Foshan Hafary Trading Co. (a wholly owned export agent that widens procurement), Guangdong ITA Element Building Materials Co. (designing and producing glazed porcelain tiles), and the newly acquired MML Shanghai Trading Co. (which contributed to project revenue growth in FY2025). Combined China revenue reached S$8.5 million in FY2025. Indonesia generated S$7.8 million, making it the fourth-largest market by revenue, ahead of China, and yet rarely discussed. In Vietnam, Hafary’s associate, Viet Ceramics International Joint Stock Company, was the group’s first foray into overseas tile retailing. It is carried at S$18.7 million on the balance sheet and contributed S$1.3 million in share of profit in FY2025, making it a quietly profitable investment despite the weakening Vietnamese Dong. In Myanmar, a joint venture (Hafary Myanmar Company Limited) contributed S$0.8 million in share of profit on S$2.1 million in revenue, a solid margin for an early-stage market entry. Smaller but growing presences in Taiwan (S$3.2 million), Thailand (S$835K), Cambodia (S$679K), the Philippines (S$570K), and Australia (S$356K) round out an ASEAN-wide distribution network that is still in its early stages but clearly by design, not by accident.

The strategic logic is clear: each entity serves a different function (sourcing, manufacturing, distribution, or retail) and together they form a regional platform that gives Hafary multiple levers for growth beyond its dominant Singapore base.

But has the international expansion actually delivered? A track record assessment.

Hafary has been promising overseas expansion since at least AR2014, when the corporate profile noted it would “continue to explore overseas opportunities.” Tracking the annual reports year by year reveals a mixed but instructive record.

Vietnam: the longest-running bet (10+ years). Viet Ceramics International (VCI) was described as Hafary’s “first foray into the overseas tile retailing market” as early as the AR2014. By AR2015, it was a clear success: profit contribution of S$2.1 million, five showrooms across Vietnam (including new openings in Ho Chi Minh City’s Phu My Hung district in February 2015 and Hanoi in March 2016), and an Outdoor Sales Department - all credited to Vietnam’s 6.68% GDP growth. By AR2020, COVID had cut VCI’s profit contribution 55.7% to S$1.8 million, down from S$4.0 million in FY2019. By FY2025, the profit share had shrunk further to S$1.3 million, and the carrying value of the associate dropped by S$1.7 million due to the weakening Vietnamese Dong. Vietnam was supposed to be the proof of concept for overseas retail expansion, and it has been consistently profitable, but after more than a decade, it has never scaled beyond a modest profit contributor, and returns are trending in the wrong direction.

China: patient, multi-layered build-out. In AR2014, China was just Foshan Hafary Trading, an export agent. By AR2015, Hafary had completed the refurbishment of a 441,000 square-foot warehouse in Gaoming, Guangzhou, positioned as a logistics hub near a port for quick inventory shipping, with unused space leased for rental income. A pragmatic, low-risk move. By AR2020, a new entity had appeared: Guangdong ITA Element Building Materials Co., which moved Hafary from trading into actual glazed porcelain tile production in China. By FY2025, a third entity, MML Shanghai Trading, acquired from MMSB for S$2.8 million, expanded the project sales base, and combined China revenue reached S$8.5 million. China has been the most disciplined international expansion: each step was functional (sourcing → logistics → production → sales), each was relatively low-cost, and none was oversold in the annual reports. It has quietly become a meaningful market.

Myanmar: the risk that hasn’t killed the venture yet. Hafary Myanmar Company Limited entered a market with high construction growth and low competition. By AR2020, the CEO’s Statement acknowledged the elephant in the room: “With the recent developments in Myanmar arising from the military coup bringing uncertainty and unrest to the country, the performance of Hafary Myanmar may be affected in the next financial year.” That warning was prescient - but remarkably, the JV survived. By FY2025, it was generating S$2.1 million in revenue and S$0.8 million in profit share. The margins suggest it has carved out a viable niche, but the political risk remains existential and largely uncontrollable.

Malaysia: the slow-burn Hap Seng promise that eventually delivered. The AR2015 set expectations clearly: “The business combination between the Company and HSCB is expected to create strong synergistic benefits, as Hafary’s business as a downstream player is complementary to HSCB’s existing involvement in the building materials upstream market segment.” By AR2020, five years after the deal, the synergies had barely materialised. Hafary Trading Sdn Bhd was only incorporated in September 2020 as a wholly owned subsidiary “to capture any potential trading and distribution opportunities in future.” It took until June 2023, eight years after the Hap Seng deal closed, for the manufacturing segment to commence production at the Kluang facilities. But once it did, the results came fast: manufacturing revenue reached S$63.1 million by FY2025, Malaysia became the second-largest market at S$54.5 million, and the US emerged as an entirely new S$35.7 million export market - none of which was even hinted at in earlier annual reports. The Hap Seng synergy promise was real, but it required far more patience than the original framing suggested.

The US: the unannounced success. Not mentioned in any annual report prior to the manufacturing launch, the US went from zero to S$35.7 million in revenue by FY2025, driven entirely by manufactured tile exports from Malaysia. This is perhaps the strongest evidence that the manufacturing pivot has strategic merit. It unlocked a market that the distribution business alone could never have reached.

The scorecard: Malaysia and the US are unambiguous wins, albeit ones that took eight years to materialise. China has been a patient, disciplined build with solid progress. Vietnam has been consistently profitable but is stagnating and exposed to currency risk. Myanmar is profitable against the odds but remains a wild card. The pattern that emerges is that Hafary’s international expansion works best when it is connected to the Hap Seng manufacturing infrastructure (Malaysia, US, China via MML Shanghai) and is more fragile when it depends on standalone retail operations in developing markets (Vietnam, Myanmar). This distinction matters for how investors should weigh the international growth optionality in the bull case.

Industry Overview: Riding Singapore’s Construction Supercycle

The timing of Hafary’s expansion coincides with what analysts describe as a multi-year construction supercycle in Singapore.¹ BCA’s January 2026 release projects construction demand of S$43–46 billion in 2026,² while Hafary’s Chairman’s Statement cites a BCA forecast range of S$47–53 billion³ - the difference likely reflecting the inclusion of different project categories. Either way, the pipeline is substantial, supported by mega-projects including Changi Airport Terminal 5, the Tuas Megaport expansion, Marina Bay Sands IR2, and the ongoing HDB BTO programme.⁴

Singapore’s construction market is valued at approximately USD 25 billion (2025), projected to reach USD 34 billion by 2031 at a 5.4% CAGR.⁵ Medium-term annual demand is forecast at S$39–46 billion per year through 2030.²

For a company that supplies the finishing materials for virtually every type of construction project, this pipeline represents years of sustained downstream demand.

Competitive Advantages and Moat

Hafary’s moat rests on several interlocking advantages.

Market dominance in Singapore tiles. An estimated 50–60% share of the general consumer tile market. This was built over more than four decades through showroom network effects, supplier relationships, and brand recognition among renovation contractors and interior designers (the key decision-influencers in tile purchases).

Entrenched supplier relationships. Hafary is the exclusive Singapore distributor for Antolini, the Italian premium natural stone brand, according to the company. Decades of sourcing relationships with European and Asian manufacturers give the company access to products and pricing that new entrants cannot easily replicate.

Vertical integration via manufacturing, enabled by Hap Seng. The Kluang, Johor manufacturing facilities are strategically significant. They reduce dependence on third-party imports, improve gross margins on manufactured products, enable export to markets like the US (where S$35.7 million in revenue was generated in FY2025), and give Hafary control over quality and lead times. But this capability did not arise organically, it was made possible by Hap Seng’s 2015 acquisition and the subsequent integration with Malaysian Mosaics (MMSB), which brought six decades of ceramic manufacturing expertise and three existing Johor production facilities. Hafary’s manufacturing moat is inseparable from the Hap Seng relationship.

Property asset base. Hafary owns significant real estate: the 161 Lavender Street conservation shophouse block (acquired for S$71.3 million, now operating as Hafary House) and the World Furnishing Hub at 18 Sungei Kadut Street 2 (independently valued at S$72 million). These assets provide operating utility and represent embedded value on the balance sheet.

Durability of the moat: The distribution network and brand are durable; tiles are a fragmented, relationship-driven market, and switching costs for contractors are real (familiarity with product range, credit terms, delivery reliability). The manufacturing moat is earlier-stage and still needs to prove sustained profitability. The Hap Seng relationship is both an enabler and a dependency: it accelerates growth but concentrates strategic risk in a single controlling shareholder.

Financial Performance: A Decade in Numbers

The 10-year financial trajectory tells a clear story: steady pre-COVID growth, a pandemic dip, and then an explosive post-2020 recovery.

Revenue grew from S$109.6 million in FY2016 to S$287.0 million in FY2025, a 2.6x increase, representing an 11.3% CAGR. The manufacturing segment, which did not exist before FY2023, accounted for S$63.1 million of FY2025 revenue.

EBITDA expanded from S$16.5 million to S$70.9 million over the same period, with EBITDA margins improving from 15.1% to 24.7%. The margin improvement is notable: it suggests the business has operating leverage, and that the manufacturing segment (despite still being in ramp-up) has not diluted group profitability.

PATMI peaked at S$39.1 million in FY2023, driven by strong distribution margins and the initial ramp of manufacturing. FY2024 included a one-off gain of S$3.7 million on disposal of an investment property. FY2024 saw a normalisation to S$27.6 million before recovering to S$29.9 million in FY2025.

ROE has been consistently strong, averaging over 20% in recent years. FY2022 and FY2023 saw extraordinary ROE of 35% and 37% respectively, driven by profit growth on a still-modest equity base. FY2025 ROE of 21.7% remains well above cost of equity.

Balance sheet and leverage: Total assets have grown to S$509.8 million, driven by property acquisitions (161 Lavender Street, Sungei Kadut) and manufacturing capex. Net debt peaked at S$275.6 million in FY2024 and has since declined to S$255.1 million in FY2025. The net debt-to-equity ratio has improved from 2.7x in FY2022 to 1.7x in FY2025, still elevated but trending in the right direction. Interest cover stands at a comfortable 6.6x.

Operating cash flow was strong in FY2025 at S$57.9 million (vs S$22.6 million in FY2024), reflecting improved working capital management and higher profits.

Dividends have been consistently paid and growing. DPS increased from 1.0 cent in FY2016 to 2.75 cents in FY2025, with the current yield at approximately 5.5%. The payout ratio has moderated from over 50% in earlier years to around 40% in FY2025, suggesting room for further increases as earnings grow.

Key Growth Drivers (Next 3–5 Years)

1. Manufacturing segment reaching profitability. The segment has grown from zero to S$63 million in revenue in just over two years but is still moving towards breakeven at the operating level. Analysts expect breakeven by FY2026. If manufacturing achieves a 10–15% operating margin at scale, it could add S$6–10 million in incremental profit to the group.

2. Singapore construction supercycle. With S$43–53 billion in annual construction demand projected by BCA through 2030, Hafary’s core distribution business has a multi-year tailwind. Terminal 5, Tuas Port, MBS IR2, and ongoing HDB BTO provide sustained downstream demand for tiles and surfacing materials.

3. US and international export growth. US revenue grew from near zero to S$35.7 million in FY2025, driven by manufactured tile exports from Malaysia. If US construction demand holds and Hafary expands its distribution network, this could become a meaningful profit contributor.

4. Malaysia as a dual platform. Malaysia serves both as a market (S$54.5 million in revenue) and a manufacturing base. Growth in Malaysian construction (forecast 6.1% in 2026) supports both sides.

5. ASEAN and China network maturing into profit contributors. The web of associates, JVs, and subsidiaries across Asia is no longer just a seeding exercise, it is generating real returns. The Vietnam associate contributed S$1.3 million in profit share, the Myanmar JV contributed S$0.8 million, and Indonesia is already a S$7.8 million revenue market. China revenue reached S$8.5 million with the MML Shanghai acquisition expanding the project sales base. If even a few of these markets scale to S$15–20 million in revenue each over the next 3–5 years, the group’s revenue base diversifies meaningfully beyond its Singapore-Malaysia-US core, reducing concentration risk and opening new profit pools.

6. Property asset monetisation. The 161 Lavender Street and Sungei Kadut properties (combined ~S$143 million in acquisition/valuation) are carried at cost on the balance sheet. Any revaluation, partial divestment, or yield enhancement from Hafary House operations could unlock value.

Major Risks and Bear Case Scenarios

Leverage remains elevated. Net debt of S$255 million against shareholders’ equity of S$146 million (1.7x) is manageable but leaves limited room for error. A significant downturn in construction activity or a rise in interest rates could squeeze cash flows. Borrowing rates currently range from 1.5% to 5.4%.

Manufacturing execution risk. The segment is not yet profitable at the operating level. If production quality issues arise, demand softens, or US trade policy changes (tariffs on Malaysian exports), the manufacturing bet could become a drag on returns.

Customer and revenue concentration in Singapore. Despite geographic diversification, Singapore still accounts for 60% of revenue. A sharp construction downturn in Singapore would hit the core business hard.

Inventory and working capital intensity. Inventories stood at S$124 million at FY2025 year-end (266 days of turnover). This is characteristic of the business but ties up significant capital and creates impairment risk if demand weakens.

Key man risk. Founder-CEO Low Kok Ann has led the business since 1980. Succession planning and management depth beyond the founding family are important considerations.

Thin trading liquidity. Average daily volume of ~20,860 shares means institutional investors may struggle to build or exit positions. This limits the re-rating potential in the near term.

Management Quality and Capital Allocation

Understanding Hafary’s management requires understanding the 2015 ownership transition because it fundamentally reshaped who runs the company and why.

Before 2015: a family business. Low Kok Ann founded Hafary in 1980 and built it into Singapore’s leading tile distributor over three decades. By 2014, the Low family collectively controlled about 54% of the company: Low Kok Ann held 15.85%, his son Low See Ching (then CEO) held ~28.7% through direct and nominee accounts, and daughter Dr Low Bee Lan Audrey held 9.58%. Property developer Ching Chiat Kwong (co-founder of Oxley Holdings) held ~19%. It was, in every sense, a founder-led, family-run business.

The 2015 Hap Seng deal: trading control for scale. On 31 December 2014, Malaysia-listed Hap Seng Consolidated Berhad announced a voluntary partial cash offer to acquire 51% of Hafary at S$0.24 per share, a total consideration of S$52.5 million. The Low family and Ching Chiat Kwong gave irrevocable undertakings to accept, collectively selling down their stakes to make room for Hap Seng’s 51% block. The deal closed in early 2015. Low See Ching had already stepped down as CEO and been redesignated as Non-Independent Non-Executive Director in January 2014, with his father Low Kok Ann taking over as CEO.

The logic was strategic. Hap Seng’s building materials arm, anchored by Malaysian Mosaics Sdn Bhd (MMSB), a tile manufacturer since 1964, was upstream (manufacturing). Hafary was downstream (distribution) with dominant Singapore market share. The combination created an integrated building materials platform. The Low family gave up majority control but retained significant skin in the game and kept operational leadership. They traded control for access to Hap Seng’s manufacturing infrastructure, capital, and regional network.

Today: a dual-power structure. The company is effectively co-governed by two forces. Hap Seng holds 50.82% and provides two board seats (Datuk Edward Lee Ming Foo and Cheah Yee Leng, both appointed March 2015), manufacturing know-how through MMSB, corporate management services, and access to regional networks. The Low family holds ~39.1% combined (Low Kok Ann 8.56%, Low See Ching 25.44%, Low Bee Lan Audrey 5.14%) and provides the operational leadership; Low Kok Ann remains CEO, with a seasoned operational team built over decades in the tile industry.

This is not a typical parent-subsidiary relationship where the controlling shareholder dictates strategy. The founder is still CEO, his family still holds 39% and is deeply embedded in operations. But Hap Seng’s majority stake means they have the votes on any matter that goes to shareholders. The alignment has worked well so far, revenue has tripled and the manufacturing segment would not exist without it, but it is an unusual governance structure that depends on continued alignment between the Lau family (Hap Seng’s ultimate controllers) and the Low family.

Capital allocation has been aggressive but largely sound. The 161 Lavender Street acquisition (S$71.3 million) was a bold move that gave Hafary both a flagship showroom and a heritage property asset. The manufacturing push into Malaysia required significant capex but is now generating S$63 million in revenue and approaching breakeven. Dividend policy has been consistent: the company has paid dividends every year through the cycle, including during COVID, and has progressively increased DPS from 1.0 cent to 2.75 cents.

Recent governance improvements include the appointment of two new independent directors in July 2024 and a new CFO, strengthening the independent voice on a seven-member board that otherwise has two Hap Seng representatives and two Low family-linked directors.

The Hap Seng Connection: Parent Company, Partner, and Platform

Hap Seng Consolidated Berhad (Bursa: 3034) is a Malaysian conglomerate with a market cap of approximately RM 7.3 billion (~S$2.1 billion), operating across six segments: automotive (one of Southeast Asia’s largest Mercedes-Benz dealers), property development, plantations (oil palm), credit financing, trading (fertilizers and agro-chemicals), and building materials. Per public market data, it reported revenue of RM 5.63 billion and net profit of RM 650 million in FY2024.

The building materials connection runs deep. Hap Seng’s building materials arm includes Malaysian Mosaics Sdn Bhd (”MMSB”), one of Malaysia’s oldest ceramic tile manufacturers, founded in 1964, with products sold in over 50 countries under the MML brand. MMSB operates three production facilities in Johor, the same state where Hafary’s own manufacturing operations are based. This is not a coincidence. Notably, Hap Seng recently reorganised its ceramic tiles business under MMSB to the Building Materials Division under Hafary Holdings, a signal that Hafary is becoming the group’s primary building materials platform rather than just a subsidiary. Hafary’s rapid scaling of its manufacturing segment, from zero to S$63 million in revenue in just over two years, would have been far more difficult without access to MMSB’s six decades of production know-how, established facilities, and distribution infrastructure.

The interested person transaction disclosures reveal the breadth of commercial dealings between the two groups:

Total interested person transactions with the Hap Seng group amounted to S$7.5 million in FY2025 (down from S$20.1 million in FY2024, when tile purchases from MMSB were significantly higher at S$12.3 million). The FY2025 figures include a notable one-off: the S$2.8 million acquisition of MML Shanghai Trading Co., Ltd. from MMSB, which expanded Hafary’s project revenue base in China.

Beyond the Hap Seng relationship, there is also a secondary network of interested person transactions linked to director Low See Ching, including rental income from The Assembly Place Holdings (S$207K), property management fees to TAP Co-livings (S$336K), and the earlier S$4.5 million acquisition of the remaining 19% stake in World Furnishing Hub from Low See Ching in FY2024.

Governance considerations. With 50.82% control and only 10.04% of shares in public hands, minority shareholders have limited influence over strategic decisions. The interested person transactions, while disclosed and conducted under shareholders’ mandate, require ongoing scrutiny to ensure arm’s-length pricing. The presence of two Hap Seng representatives on a seven-member board concentrates influence. Investors should satisfy themselves that the governance framework, including the three independent directors and the Audit Committee’s oversight of IPTs, provides adequate safeguards.

An Alternative Route: Hap Seng vs Hafary as an Investment

An investor interested in Hafary’s building materials story might reasonably ask: should I buy the subsidiary directly, or buy the parent at a conglomerate discount?

The numbers reveal a clear trade-off. Hap Seng trades at 0.92x book value, a discount to its RM 3.19 NTA per share, with lower leverage (0.37x net debt/equity vs Hafary’s 1.7x) and a higher dividend yield (~6.8% vs ~5.5%). It is a more conservative, diversified holding. But its ROE is a modest 8.2%, its earnings have been declining (PATMI fell from RM 951 million in FY2022 to RM 650 million in FY2024), and its revenue has contracted for two consecutive years.

Hafary, by contrast, is a higher-octane bet: 21.7% ROE, 11.3% revenue CAGR over the past decade, and a clear growth trajectory from its manufacturing expansion. But it comes with higher leverage and a much thinner public float.

The critical exposure question: Hap Seng’s 50.82% stake in Hafary is worth approximately S$109 million (RM 371 million) at current market prices, just 5.1% of Hap Seng’s RM 7.3 billion market cap. Buying Hap Seng gives you a small slice of Hafary diluted across Mercedes-Benz dealerships, palm oil plantations, property development, and fertilizer trading. Buying Hafary gives you 100% pure-play building materials exposure to Singapore’s construction supercycle.

Neither is inherently better, they just serve different investment objectives. Hap Seng suits an investor seeking a diversified, income-generating Malaysian conglomerate trading below book value. Hafary suits an investor with conviction in the Singapore construction cycle and Hafary’s manufacturing pivot, willing to accept higher leverage and lower liquidity for concentrated upside.

Valuation

At S$0.50 per share, Hafary trades at 7.2x trailing P/E, approximately 6.6x EV/EBITDA (based on enterprise value of ~S$470 million and EBITDA of S$70.9 million), and 1.5x P/B (based on NAV of 33.9 cents per share). Dividend yield is approximately 5.5%.

These multiples are low relative to the broader Singapore construction sector. The discount likely reflects Hafary’s small-cap status, thin liquidity, the still-unproven manufacturing segment, and elevated leverage.

NAV perspective: NAV per share of 33.9 cents likely understates intrinsic value because key properties (161 Lavender Street, Sungei Kadut) are carried at historical cost. An independent valuation of the Sungei Kadut property alone was S$72 million, suggesting meaningful embedded value not reflected in the book.

Earnings perspective: At current earnings levels, the multiple is undemanding. Investors should consider whether the manufacturing segment’s path to profitability and the construction supercycle justify a higher or lower multiple, and form their own view accordingly.

Recent Developments and Catalysts

The twelve months to April 2026 have been eventful and the market has started to take notice. Hafary’s share price has risen approximately 49% over the past year, from a 52-week low of S$0.32 to trade around S$0.50, though it remains well below the 52-week high of S$0.60.

FY2025 results (released February 2026) delivered across every metric that matters. Revenue grew 9.1% to S$287 million. Gross margins expanded from 40.3% to 41.1%, indicating that the revenue mix is improving, not just growing. Operating cash flow more than doubled, from S$22.6 million to S$57.9 million, the strongest in recent memory. Net debt declined by S$20.5 million to S$255.1 million, and finance costs fell 12% to S$10.7 million as bank loan interest rates eased. The balance sheet, which had been a persistent concern, is healing.

Hafary House officially opened in January 2025, a 10,000 square-foot luxury flagship showroom at 161 Lavender Street, following a S$3 million refurbishment of the conservation shophouse block. This is more than a showroom upgrade. It positions the Hafary brand in the premium residential segment, targeting GCB owners, high-end renovation projects, and architectural firms, a market where margins are higher and brand differentiation matters more. The ground floor houses F&B and commercial tenants, while upper floors are managed as co-living spaces by The Assembly Place, generating rental income from the property.

Hap Seng reorganised its ceramic tiles business under Hafary. In a structural move that signals Hafary’s growing importance within the group, Hap Seng transferred the Building Materials Division, including MMSB’s operations, to sit under Hafary Holdings rather than as a separate Hap Seng division. This consolidation positions Hafary as the group’s primary building materials platform across the region, not merely a downstream distributor. It also suggests Hap Seng views Hafary’s management as capable of running a larger, more integrated operation.

MML Shanghai was acquired and consolidated from January 2025, expanding Hafary’s project revenue base in China. The S$2.8 million acquisition from MMSB brought a ready-made sales entity that contributed to the 2.2% project segment revenue growth in FY2025, a modest start, but it establishes Hafary’s direct presence in China’s project market for the first time.

Board and management refreshment. Two new independent directors were appointed in July 2024: Darrell Lim (who also sits on the board of BRC Asia Limited (SGX: BEC), Singapore’s largest steel reinforcement supplier) and Lim Wah Fong (with over 20 years of capital markets experience as a research analyst and senior portfolio manager). A new CFO was also appointed. These moves strengthen the independent voice on a seven-member board and bring capital markets expertise at a time when the company could benefit from improved investor communication and coverage.

Macro tailwinds for SGX small/mid-caps. The Straits Times Index broke historical highs and crossed 5,000 during 2025, and as noted in Hafary’s own Chairman’s Statement, “capital market stakeholders are predicting further upside by the end of 2026.” The ongoing MAS EQDP capital injection programme and SGX’s Value Unlock initiative are channelling institutional attention towards under-covered small and mid-cap stocks, exactly the category Hafary falls into, with its S$215 million market cap, 10% public float, and minimal analyst coverage.

Bull vs Bear Investment Thesis

The Bull Case: Hafary is a dominant market leader in an essential, non-discretionary construction material, trading at undemanding multiples relative to peers. The manufacturing segment is inflecting towards profitability, which could add S$6–10 million in incremental profit. Singapore’s multi-year construction supercycle provides a long runway for the core distribution business. US export growth adds a new dimension. The breadth of the international network, profitable associates in Vietnam, a producing JV in Myanmar, established revenue streams in Indonesia (S$7.8 million), China (S$8.5 million), and a dozen other markets, means the company has multiple optionalities beyond its Singapore core. If even two or three of these markets scale meaningfully, the revenue base diversifies in ways the current valuation does not reflect. Property assets are undervalued on the balance sheet. Consistent dividend payments provide a meaningful yield while investors wait.

The Bear Case: Leverage is elevated and leaves limited cushion for a downturn. Manufacturing is unproven at scale and may struggle to achieve sustainable margins, particularly if US tariff policy shifts. Singapore construction demand could soften if mega-projects face delays or if the economy slows. The international expansion, while promising, also introduces execution complexity: managing subsidiaries, associates, and JVs across 15 countries requires management bandwidth and exposes the group to currency risk (the Vietnamese Dong weakened materially in FY2025, reducing the carrying value of the Vietnam associate by S$1.7 million), political risk (Myanmar remains unstable), and the challenge of maintaining quality and brand consistency across fragmented markets. Inventory of S$124 million represents significant impairment risk. Thin liquidity (10% public float, ~20,860 shares daily volume) means the stock could be volatile. CEO Low Kok Ann has led the business since 1980, succession planning is a genuine concern given the dual-power structure between the Hap Seng and Low families. The alignment between the Lau family (Hap Seng’s controllers) and the Low family has worked well so far, but any divergence in strategic priorities could create governance friction. And for investors used to more liquid, widely-held stocks, the concentrated ownership structure may be a structural deterrent.

Key Factors That Could Break the Thesis

On the bull side, watch for: manufacturing segment turning profitable (analysts expect breakeven by FY2026), sustained revenue growth above S$300 million, net debt-to-equity declining below 1.5x, Indonesia or China revenue crossing S$15 million (signalling a third pillar market is maturing), any property revaluation or strategic asset move, and increased analyst coverage or institutional interest.

On the bear side, watch for: construction demand falling below BCA forecasts, manufacturing margins remaining negative beyond the expected FY2026 breakeven, a spike in interest rates increasing finance costs materially (currently S$10.7 million), impairment charges on inventory or receivables, write-downs of international associates or JVs (particularly if Myanmar deteriorates or the Vietnam Dong continues weakening), and any regulatory or trade policy changes affecting Malaysian exports to the US.

Summary

Hafary Holdings has evolved from a single-product tile trader into a S$287 million revenue platform spanning distribution, project supply, and manufacturing across multiple geographies. The company’s 50–60% share of Singapore’s general consumer tile market, built over more than four decades, is a genuine competitive advantage, and one that is difficult to replicate.

The 2015 Hap Seng acquisition was the pivotal inflection point. It transformed a family-run distributor into the building materials arm of a RM 7.3 billion Malaysian conglomerate, giving Hafary access to manufacturing infrastructure, regional networks, and capital that it could not have built alone. The Low family’s decision to trade majority control for scale has, by the numbers, paid off handsomely: revenue has tripled, a new manufacturing segment has emerged, and the company is now exporting tiles to the US. But it also created an unusual governance structure, the original founder still running day-to-day operations, a Malaysian conglomerate holding 50.82%, and a public float of just 10%, that investors need to understand and be comfortable with.

The financial track record is strong: revenue has grown at an 11.3% CAGR over the past decade, EBITDA margins have expanded from 15% to nearly 25%, and ROE has consistently exceeded 20% in recent years. Dividends have been paid every year through the cycle, including during COVID.

The key question facing the business is whether the manufacturing segment, still approaching breakeven, can deliver on its promise of margin expansion and export-driven growth. If it does, Hafary’s earnings power steps up meaningfully. If it doesn’t, the company remains a well-run distributor with elevated leverage from its aggressive expansion phase.

On the macro side, Singapore’s multi-year construction supercycle provides a supportive backdrop, but this is not a risk-free tailwind: project delays, interest rate movements, and trade policy shifts all matter for a company with S$255 million in net debt.

For those considering the building materials theme but preferring a different risk profile, the parent company Hap Seng Consolidated offers a diversified alternative at 0.92x book value with lower leverage and a higher dividend yield, though with only ~5% exposure to Hafary’s story.

References

All financial data sourced from Hafary Holdings annual reports (FY2010–FY2025) and SGX announcements. Market data from public sources as of April 2026

¹ DBS Group Research, "From Backlog to Breakout," March 2026, https://www.dbs.com.sg/sme/aics/templatedata/article/generic/data/en/GR/032026/260302_insights_sg_construction.xml

² BCA Media Release, 22 January 2026, "Steady Construction Demand in 2026," https://www1.bca.gov.sg/resources/newsroom/steady-construction-demand-in-2026-as-singapore-steps-up-support-for-built-environment-firms-through-collaboration-and-innovation/

³ Hafary Holdings AR2025, Chairman and CEO Statement, p.14, citing BCA-REDAS Built Environment and Real Estate Prospects Seminar 2026.

⁴ Hafary Holdings AR2025, Chairman and CEO Statement, p.14.

⁵ Mordor Intelligence, "Singapore Construction Industry Report," https://www.mordorintelligence.com/industry-reports/singapore-construction-market; also cited in GlobeNewsWire, 23 February 2026.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Hafari Holdings’ SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

The disconnect between operational performance and share price warrants closer examination. This report walks through the full picture.

The Business: How Coliwoo Makes Money

Coliwoo acquires or leases old, underutilised buildings across Singapore, converts them into co-living spaces, and operates them. The business model combines value-add real estate repositioning with a hospitality operations platform. As of the IPO prospectus, the portfolio spanned 25 properties and 2,933 rooms across three tiers. With the completion of the S$101M Changi Business Park acquisition in Q1 FY2026, the portfolio has grown to approximately 3,200 rooms.

Leased properties (~71% of FY2024 revenue, 1,855 rooms at IPO): Coliwoo signs master leases with building owners, pays fixed rent, and captures the spread between rent cost and tenant revenue. The largest single property is 2 Mount Elizabeth Link in Orchard (411 rooms). This is the core of the business — capital-light, scalable, but exposed to lease renewal risk.

Owned properties (~26% of FY2024 revenue, 670 rooms at IPO): Higher capital intensity, better long-term economics. Includes properties across River Valley, Balestier, Beach Road, and Arab Street. Owned property occupancy improved from 73% in FY2022 to 95.5% in 1H2025.

Managed properties (~3% of FY2024 revenue, 408 rooms): Pure fee income. Includes two MOHH contracts for healthcare worker housing and — notably — two properties owned by CEO Kelvin Lim’s personal entities (classified as Interested Person Transactions).

The dual hotel/residential licensing model is worth noting. Some properties hold hotel licenses (allowing 1-night stays), while others operate under residential co-living rules (3-month minimum). This flexibility allows Coliwoo to fill short-stay gaps with tourist traffic during low seasons.

The Numbers: Strong, But Read the Fine Print

*) FY2025 revenue decline partly due to non-recurrence of one-time retrofitting income; owned rental income +23.9%
**) Reported PATMI distorted by fair value swings on investment properties

A note on accounting basis: Coliwoo’s prospectus presents FY2022-FY2024 financials on a pre-SFRS(I)16 basis, while the FY2025 annual report uses SFRS(I)16. This matters — SFRS(I)16 capitalises leases, which changes revenue recognition and margin calculations. Revenue figures and margins may not be directly comparable across periods without adjustment.

On a pre-SFRS(I)16 basis (prospectus data), revenue grew from S$19.8M in FY2022 to S$52.2M in FY2024. FY2025 revenue on an SFRS(I)16 basis was S$46.7M, though the decline partly reflects the non-recurrence of one-time retrofitting income — owned rental income actually rose 23.9%.

The metric that matters is core PATMI. Reported net profit is unreliable for Coliwoo because fair value swings on investment properties create wild distortions (S$14.9M gain in FY2024, S$7.4M loss in FY2025). Strip those out, along with IPO costs and share of associate/JV results, and the picture becomes clearer. On this core basis, management reported that FY2025 core PATMI surged 62.6% year-on-year to approximately S$22.9M. The three-year trajectory from S$7.0M (FY2022 adjusted, pre-SFRS(I)16 basis) to S$22.9M represents a 48% CAGR — though comparing across accounting bases requires caution.

Gross margins have been in the 60-75% range on a pre-SFRS(I)16 basis (74.7% in FY2022, 54.6% in FY2023, 60.2% in FY2024) and reached 70.8% in 1H2025. The FY2023 dip reflects the rapid scaling of new leased properties before they reached full occupancy. Operating cash flow jumped from S$15.4M to S$24.8M in FY2025. Working capital dynamics are favourable: tenants prepay (2-4 day receivables), while Coliwoo stretches payables to 19-25 days.

The portfolio composition has shifted over time. Leased properties accounted for roughly 80% of rooms in FY2022 but have declined to about 63% as of the IPO prospectus date, as owned and managed properties grew as a share of the total. Management has diversified away from pure leased concentration — owned properties provide better long-term economics, while managed properties offer capital-light fee income.

The Moat Question: What’s Defensible?

This is where most analysis of Coliwoo falls short. An honest assessment: the moat is moderate, not structural.

What IS defensible: LHN Group sponsorship is the strongest factor. LHN retains a 65% stake, provides deal pipeline, operational expertise in space optimisation, and balance sheet backing. LHN has delivered strong total shareholder returns (397% over 5 years per one December 2025 report, though an earlier February 2024 measurement put it at 161%). The combination of 25+ properties, established brand (55K+ social media followers, multiple awards), and dual licensing flexibility creates real operational advantages.

What ISN’T defensible: The regulatory moat is almost non-existent. A URA change-of-use approval through the fast-track “deemed authorised” route costs S$150 and can be instant; the standard route costs S$500 and takes about 10 working days. Any operator with capital can enter Singapore’s co-living market. The technology “platform” is operational tooling, not defensible IP.

The competitive reality: The Assembly Place (TAP.SI, listed on Catalist in January 2026) now operates more rooms — 3,422 keys across approximately 100 assets — compared to Coliwoo’s 2,933 at IPO (now approximately 3,200). Habyt has $120M in venture funding. The top 5 operators control 65% of the market, and the sector is consolidating.

Management: What the Record Shows (And Doesn’t)

Kelvin Lim founded Coliwoo in 2018 within LHN Limited, secured a Mainboard listing, and attracted cornerstone investors including Maybank AM, UOB AM, and Value Partners. The execution track record is strong. In seven years, the business grew from zero to over 3,000 rooms.

However, several aspects warrant scrutiny. The prospectus — all 800 pages of it — does not disclose Kelvin Lim’s age, education, or prior career history beyond his role at LHN. That is unusual for a Mainboard listing. He serves as Executive Chairman AND CEO, concentrating significant authority. Two managed properties are owned by his personal entities (Interested Person Transactions, though small at 57 rooms).

The parent company picture is also worth noting. LHN’s ROE is 7.9% — weak for a real estate operator. Consensus expects LHN’s EPS to decline 8.5% in FY2025. Coliwoo contributes 56% of LHN’s 1H2025 pre-tax profit — a substantial dependency. If Coliwoo’s growth slows, LHN’s financials deteriorate, which could reduce the parent’s capacity to support expansion.

Recent capital allocation has been aggressive but strategic: a S$43.9M sale-leaseback (capital recycling), S$40M JV acquisition, and the S$101M Changi Business Park deal. The 40% dividend payout policy balances returns with reinvestment. The question is whether these investments generate returns that justify the capital deployed — something that will only become clear in 12-18 months.

Occupancy: The Headline Number Needs Context

The 96.8% portfolio-level occupancy (as of 1H2025) is strong. The Q1 FY2026 business update reported 96.5% as of January 31, 2026.

Breaking it down by property type, the data available from the prospectus shows: Owned properties improved from 73.0% in FY2022 to 95.5% in 1H2025 — strong execution on a previously underperforming segment. Leased properties were at 97.3% in FY2022 and 96.6% in 1H2025. Managed properties run at 98.7%, largely driven by MOHH healthcare contracts with guaranteed demand. (Note: Intermediate-year occupancy breakdowns by property type are not fully disclosed in the prospectus or annual report.)

The risk is that 96.8% occupancy leaves almost no room for improvement — it can really only go sideways or down. As Coliwoo targets adding 800-1,000 rooms annually, maintaining near-full occupancy during ramp-up periods for new properties will be a challenge worth monitoring.

Valuation: Context Matters More Than Headline Multiples

At S$0.50 per share (480.8M shares outstanding):

• Market cap: ~S$240M

• P/E on FY2025 core PATMI (~S$22.9M): ~10.5x

• Price/Book: ~1.87x (equity S$128.1M)

• Dividend yield: ~3.5% (based on 40% payout policy)

• EV/EBITDA: ~16x

The 10.5x P/E is not obviously cheap for a Singapore-listed small-cap property operator with moderate competitive moats. Both Coliwoo and Assembly Place trade below their IPO prices — the market has repriced co-living sector expectations.

A directional fair value estimate, assuming 20% core PATMI growth for 3 years followed by 10% for 2 years, a terminal growth rate of 3%, and a 10% discount rate, points to approximately S$0.55-0.60 per share. This is a rough estimate, not a rigorous DCF model, and the result is sensitive to growth assumptions. The 10-20% potential upside provides a thin margin of safety, given execution uncertainties.

The January 2026 analyst target of S$0.74 (from a single visible coverage initiation) implies roughly 48% upside from today’s price. With limited analyst coverage and the target predating several months of trading, it should be treated as one data point rather than an anchor.

Key Catalysts to Monitor

Bullish triggers: Changi Business Park occupancy ramp (250+ rooms), FY2026 core PATMI exceeding S$28M (confirming growth trajectory), any concrete regional expansion deal, continued MSCI-driven institutional interest.

Bearish triggers: Occupancy falling below 90%, non-renewal of 2 Mount Elizabeth Link lease (411 rooms = ~13% of expanded portfolio), LHN financial deterioration, or management turnover.

Assessment

Coliwoo is a well-run business in a growing market with real operational strengths. The 96.8% occupancy, strong gross margins, and 48% core PATMI CAGR over three years are notable.

But “good business” and “good investment at this price” are different questions. The moat is moderate, the competitive position is being challenged by The Assembly Place and well-funded private operators, the parent company shows earnings weakness, and the margin of safety at S$0.50 appears thin.

The bull case rests on: the 48% core PATMI CAGR continuing, Changi Business Park ramping successfully, MSCI inclusion driving institutional demand, and LHN’s deal pipeline delivering accretive acquisitions. If FY2026 core PATMI exceeds S$28M, the growth thesis strengthens considerably.

The bear case rests on: moderate moats in a consolidating market, Assembly Place’s larger portfolio, LHN’s declining earnings trajectory, and the risk that near-full occupancy cannot be sustained as the portfolio expands rapidly. Both co-living IPOs trading below issue price suggests the market is pricing in risks the bulls may be underweighting.

The co-living sector in Singapore has structural tailwinds — urbanisation, expatriate demand, housing affordability constraints. The question for Coliwoo specifically is whether operational advantages can compound into durable competitive advantages before well-funded competitors close the gap. The next 12 months will be telling.

Data sources: Coliwoo FY2025 audited annual report (PwC), IPO Prospectus dated 28 October 2025 (registered with MAS), Q1 FY2026 business update, SGX corporate announcements, market data as of April 2026. Financial figures prior to FY2025 are on a pre-SFRS(I)16 basis unless otherwise noted.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Coliwoo Holdings Ltd’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

Here’s what caught my attention: the company just posted record revenue of S$163.5 million in FY2025, growing 14% year-on-year. Net profit hit S$19.2 million. And yet the market values the entire company at around S$183 million, less than half the S$322 million of net assets sitting on its balance sheet.

Let’s unpack why.

What Does Tiong Woon Actually Do?

Tiong Woon is an integrated heavy lift and haulage specialist. If you need to lift 3,600 tonnes of refinery equipment in India using a pair of ultra-heavy crawlers, or hoist a beam launcher frame onto the Pan-Island Expressway, these are the people you call.

The company operates through three segments, though one overwhelmingly dominates:

Heavy Lift and Haulage (98% of FY2025 revenue, S$159.9M): This is the core business: project planning and engineering, heavy lift execution using mobile, crawler, and tower cranes, heavy haulage with modular transporters and prime movers, rigging, jacking and skidding services, and barge transportation for oversized cargo. Revenue grew 15% from S$139.4M in FY2024 to S$159.9M in FY2025.

Marine Transportation (~1%): Sea transportation using tugs and barges. A small segment but one that has been recovering: fleet utilisation improved to 35% in FY2022 after bottoming at 31% in FY2021.

Trading (~1%): Authorised dealer for XCMG products in Southeast Asia and KATO crawler cranes in ASEAN, plus parts distribution and after-sales services. Strategically useful as it supports the core heavy lift business.

The fleet is massive: 600+ cranes and heavy lifting assets, with capacities up to 2,200 tonnes. In FY2025 the company added an XCMG XGC12000 (800T) crawler crane, further strengthening its ultra-heavy lift capabilities. Plus 359 transportation assets, prime movers, low beds, trailers, and marine vessels. The company owns yards and offices across 12+ countries.

Geographically, Singapore is the dominant market at 73% of FY2025 revenue (S$119.1M). India and Thailand each contributed 7% (S$11.9M each). The balance is spread across Indonesia, Brunei, the Middle East, and other regional markets. Singapore’s share has been fairly stable in the 73–78% range over recent years.

The Numbers: A Decade of Turnaround

The financial story is one of dramatic recovery and, more recently, acceleration

The downturn years (FY2016–FY2018)

In FY2016–2017, Tiong Woon posted combined losses of nearly S$20 million. The oil and gas downturn hammered demand for heavy lift services. To make matters worse, the company took massive trade receivable impairments: S$9.8M in FY2016 and S$5.9M in FY2017, largely related to a long-outstanding receivable from Saudi Arabia that was eventually fully written off.

Revenue fell from S$139.4M in FY2016 to just S$97.7M in FY2018, the trough year. But even at the bottom, operating cash flow remained positive at S$23.9M, the underlying business was still generating cash despite the reported losses. This is an important nuance: the losses were driven more by impairments and below-the-line items than by operational cash burn.

The recovery (FY2019–FY2022)

FY2019 marked the inflection point. Revenue climbed back to S$117.2M and the company returned to profitability, albeit modestly (PATMI of S$2.9M, EPS of 1.27 cents). FY2020 saw revenue grow to S$124.7M despite the COVID-19 disruption, the company was able to continue operating in essential services sectors (oil and gas, marine, logistics) even during the Circuit Breaker.

Margins began expanding meaningfully. Gross profit margin improved from 26% in FY2018 to 35% in FY2020 and 40% in FY2022, driven by better pricing, improved fleet utilisation, and a focus on higher-value projects. The Heavy Lift and Haulage segment specifically saw margin improvement as the company invested in fleet management and cost control.

The acceleration (FY2023–FY2025)

The past three years represent the strongest financial performance in the company’s history:

• FY2023: Revenue S$135.8M (+11% YoY), PATMI S$15.7M (+38%), gross margin 39.9%

• FY2024: Revenue S$143.1M (+5%), PATMI S$18.2M (+16%), gross margin 41.2% (peak)

• FY2025: Revenue S$163.5M (+14%), PATMI S$19.2M (+6%), gross margin 37.6%

A few things stand out from the numbers:

Margin trajectory: Gross margins expanded from 23% in FY2016 to a peak of 41.2% in FY2024. FY2025 saw a pullback to 37.6%, which the annual report attributes to project sales mix and higher indirect manpower costs. The 14% revenue growth only translated to 4% gross profit growth (S$59.0M to S$61.4M), which tells us the incremental revenue came at lower margins than the existing base.

Is this a temporary blip or the beginning of margin normalisation? The answer likely depends on fleet utilisation trends. Utilisation dipped slightly from 56% in FY2024 to 54% in FY2025, even as the fleet expanded from 543 to 600+ units. That 2-percentage-point decline, combined with higher overhead from a larger fleet, explains most of the margin compression.

Other operating expenses have been growing: S$36.8M in FY2025 vs S$34.3M in FY2024 and S$25.8M in FY2021. This line includes staff costs, which have risen as the company scaled up to 1,223+ employees. These costs are somewhat sticky, they don’t shrink quickly if demand softens.

Impairment losses have shrunk dramatically, from S$3.7M in FY2020 to S$0.9M in FY2025. The company has clearly cleaned up its receivables book.

Finance costs remain moderate at S$4.2M in FY2025, though they’ve been creeping up from S$2.8M in FY2022 as borrowings increased for the FY2025 capex cycle.

EPS has grown from a loss of 4.16 cents in FY2016 to a positive 8.29 cents in FY2025, a complete transformation. The 7-year EPS CAGR from FY2018’s 0.51 cents to FY2025’s 8.29 cents is approximately 49%, though this is from a depressed base.

Balance Sheet: The Hidden Strength

Here’s where it gets really interesting for value-oriented investors.

Asset composition

Total assets grew from S$413M in FY2018 to S$532M in FY2025. The balance sheet is dominated by Property, Plant and Equipment at S$387M. That’s cranes, heavy lifting equipment, yards, and other physical assets. PPE alone exceeds the entire market capitalisation (S$183M) by more than 2x.

Right-of-use assets add another S$11.7M, and cash and bank deposits stand at S$64.5M (down from S$81.1M in FY2024, reflecting the heavy capex year). Trade receivables of S$59.0M are up from S$53.0M in FY2024, consistent with the revenue growth.

Deleveraging story

The most impressive balance sheet trend is the deleveraging. Net gearing has declined from 0.48x in FY2016 to just 0.15x in FY2025. Here’s how that played out:

Total borrowings fell from S$136M in FY2016 to a trough of S$92.8M in FY2024, while net assets grew from S$255M to S$309M over the same period. In FY2025, borrowings increased to S$111.8M to fund the major fleet expansion (S$45.2M capex), but net gearing of 0.15x is still very conservative for an asset-intensive business.

The company’s borrowings are split between current (S$21.6M) and non-current (S$90.2M). The non-current portion increased significantly in FY2025, suggesting the fleet investments are being financed with long-term facilities, a sensible match of asset life to financing tenor.

Net assets

Net assets have grown steadily from S$247.6M in FY2017 to S$322.3M in FY2025, translating to NAV per share of S$1.39. This compares to a current share price in the S$0.60–0.81 range, meaning the stock trades at 0.43x–0.58x book value.

Now, specialised heavy lift equipment may not be worth full book value in a distressed sale. Cranes and modular transporters are expensive to transport and maintain, and buyer pools are limited. But the equipment is productive and generating returns, not sitting idle. And the consistent cash generation (see next section) validates the earning power of these assets.

Cash Flow: The Real Test

One of the most important tests for an asset-heavy business: does it actually generate cash? Or do the depreciation charges mask a business that’s barely earning its cost of capital?

Operating cash flow

Operating cash flow has been consistently positive for the entire 10-year period, even during the loss years. OCF ranged from S$23.9M (FY2018, the trough) to S$54.5M (FY2020). FY2025 saw strong OCF of S$51.4M, up 30% from FY2024’s S$39.5M, driven by higher earnings and working capital improvements.

A key metric: depreciation consistently runs at S$30–35M per year (S$34.8M in FY2025, comprising S$33.9M on PPE and S$0.9M on right-of-use assets). The fact that OCF of S$51.4M comfortably exceeds depreciation means the business is generating real economic profit, not just accounting profit.

Capital expenditure cycles

Capex has been highly variable, ranging from just S$3.6M in FY2023 to S$45.2M in FY2025. This reflects the lumpy nature of fleet investment. Cranes are expensive assets purchased when specific growth opportunities justify them.

The FY2025 capex of S$45.2M is the highest in the company’s recent history and represents a major growth bet. The annual report highlights the addition of the XGC12000 (800T crawler crane) as a strategic investment to expand ultra-heavy lift capabilities. This is equipment that positions the company to compete for the largest projects in the region, the kind that previously would have gone to international players like Mammoet or Sarens.

The company partially offset the capex through disposal proceeds of S$8.8M (selling underutilised older equipment), bringing net investment to approximately S$36.4M.

Free cash flow

Free cash flow (OCF minus capex) has been positive in 9 of the 10 years, with only FY2025 essentially breakeven at S$6.2M due to the heavy investment year. The cumulative FCF over the 10-year period is approximately S$204M, which is remarkable for a company with a current market cap of S$183M, investors are essentially buying the entire company for less than one decade of free cash flow.

Dividend payments

Dividends paid have grown from zero (FY2018–2019) to S$3.5M in FY2025. Even at the current payout level, dividends represent less than 7% of OCF, leaving substantial capacity for further increases or investment.

Dividends: Small but Growing Fast

Tiong Woon suspended dividends during the downturn years (FY2018–2019) but has reinstated and progressively increased them:

• FY2020: 0.30 cents

• FY2021: 0.40 cents (0.30 regular + 0.10 special)

• FY2022: 0.50 cents (0.35 + 0.15 special)

• FY2023: 1.00 cent (0.40 + 0.60 special)

• FY2024: 1.50 cents (0.60 + 0.90 special)

• FY2025: 1.75 cents (final only, subject to AGM approval)

That’s nearly a 6x increase in six years, from 0.30 cents to 1.75 cents. At a current price of S$0.76 (midpoint), the trailing yield is approximately 2.3%.

The payout ratio remains conservative at roughly 19% of earnings. With EPS of 8.29 cents and DPS of 1.75 cents, the company is retaining over 80% of earnings for reinvestment. There’s substantial room to grow the dividend further without straining the balance sheet.

The progressive introduction of special dividends alongside regular dividends is a positive signal. It suggests management is willing to return capital to shareholders when results are strong, while maintaining flexibility by not locking in unsustainably high regular dividends

.Competitive Position and Industry Context

Tiong Woon’s competitive positioning is strengthened by several factors:

Fleet scale: With 600+ cranes ranging from small mobile units to 2,200T capacity crawlers, the company can handle projects of virtually any scale. This breadth matters because customers increasingly prefer one-stop solutions rather than engaging multiple contractors.

Track record: Decades in the business, with the kind of safety and execution record that gets you invited to bid on complex projects. Recent showcase projects include the PIE Beam Launcher Frame installation (using a 900T mobile crane and 10-axle modular transporter), a 3,600-tonne combined lift at the Numaligarh Refinery in India (deploying 1,600T and 2,200T crawler cranes to install four reactors), and heavy lifting works at Jurong Island petrochemical facilities.

Only listed pure-play in SEA: After Tat Hong Holdings was taken private in 2018, Tiong Woon became the only publicly listed pure-play heavy lift specialist in Southeast Asia. Most competitors, Mammoet (Netherlands), Sarens (Belgium), Moh Seng, Pollisum, Hiap Tong, are private. This is both a competitive dynamic (less public scrutiny on competitors) and a scarcity factor for investors who want exposure to this niche.

Mammoet MoU (FY2024): The company signed a Memorandum of Understanding with Mammoet, the global leader in heavy lift. While MoUs don’t always materialise into revenue, a partnership with the world’s largest heavy lift company could unlock projects that neither party could win alone.

The industry backdrop is favourable. Singapore’s infrastructure pipeline (Tuas expansion, MRT network extensions, petrochemical investments on Jurong Island) represents multi-decade demand. The broader SEA mobile crane market is projected to grow at 8.4% CAGR through 2029.

Ownership and Governance

Tiong Woon is family-controlled. The Ang family holds approximately 39% through Ang Choo Kim & Sons Pte. Ltd. Executive Chairman Ang Kah Hong has led the business since its early days; CEO Ang Guan Hwa (appointed 2020) represents the next generation.

The family’s significant stake creates alignment - they’re eating their own cooking. But it also means limited free float (roughly 50% retail), which constrains liquidity and institutional participation.

The board includes two independent directors who chair the Audit, Nominating, and Remuneration committees, meeting SGX’s governance requirements. Capital allocation decisions over the past decade have been sensible: deleveraging during the downturn, preserving cash, then investing aggressively into the upcycle.

Valuation: Why Is It So Cheap?

Let’s look at the numbers from multiple angles.

P/E of ~9.2x (based on FY2025 EPS of 8.29 cents at a ~S$0.76 midpoint). For a company that’s delivered 7 consecutive years of profit growth and just posted record revenue, this is modest. Regional industrial companies on SGX typically trade at 10–15x earnings.

P/B of ~0.43x–0.58x. Net asset value per share is S$1.39 versus a share price of S$0.60–0.81. The stock would need to roughly double to reach book value. While specialised equipment may carry an asset-realisation discount, the earning power of these assets is being demonstrated year after year.

EV/EBITDA of ~3.6x. EBITDA from first-party data is approximately S$63.3M (PBT S$24.4M + interest expense S$4.2M + PPE depreciation S$33.9M + ROU depreciation S$0.9M). Enterprise value is roughly S$230M (market cap S$183M + total borrowings S$111.8M – cash S$64.5M). At 3.6x EV/EBITDA, the company still trades at a significant discount to typical industrial multiples of 6–8x.

Dividend yield of ~2.3%. Not a screaming yield, but the nearly 6x growth over six years suggests this will continue climbing. If DPS reaches 3.0 cents in the next 2–3 years (plausible at a 19% payout ratio with modest earnings growth), the yield on today’s price would be ~4%.

Why the discount? Several structural factors likely explain it:

• Small market cap (~S$183M) keeps it below the radar of most institutional mandates

• Family’s 39% stake reduces free float to ~50%

• “Boring” industrial sector that doesn’t attract growth or thematic investors

• Cyclicality risk. Investors remember the FY2016–2017 losses

• Limited sell-side coverage for a micro-cap SGX name

For investors who can look past these structural factors, the valuation gap between intrinsic value and market price looks compelling.

What Could Go Right (and Wrong)

The bull case rests on:

• Singapore’s multi-decade infrastructure pipeline sustaining demand

• The XGC12000 investment unlocking ultra-heavy lift projects at premium margins

• India and Middle East scaling to 15–20% of revenue

• Continued deleveraging and dividend growth

• A potential re-rating as the market recognises the sustained earnings improvement

If EPS reaches 10–12 cents by FY2027–28 and the market assigns a more reasonable 12x P/E (still below typical SGX industrial multiples), that would imply S$1.20–S$1.44 per share. Even a modest re-rating to 0.7x P/B would yield S$0.97.

The bear case centres on:

• A macro or sector-specific slowdown hitting Singapore infrastructure spending

• The FY2025 margin compression (41% → 38%) continuing as competition intensifies

• Fleet utilisation declining from 54% towards the 48% levels of FY2022–23

• The S$45M capex not generating adequate returns if demand softens

• Currency risk from multi-country operations

In a downturn scenario, EPS could revert to 3–4 cents (the FY2020–21 range), and the stock could trade down to S$0.40–0.50 at 10–12x depressed earnings.

The base case sits somewhere in between: continued but moderating growth, margins stabilising in the 36–39% range, EPS of 8–10 cents, with the stock gradually re-rating as the dividend grows and the earnings track record lengthens.

The Bottom Line

Tiong Woon is a well-run, family-controlled industrial company with a 45-year track record, trading at a significant discount to its tangible asset value. The improving earnings trajectory, conservative balance sheet, and growing dividends all point in the right direction.

The key risk is cyclicality. This business has been through very tough times. The FY2016–2017 losses demonstrate what happens when demand turns. But the balance sheet is materially stronger today (net gearing 0.15x vs 0.48x), the receivables book is cleaner, and the company has a larger, more capable fleet positioned for the infrastructure upcycle.

At 0.5x book value, 9x earnings, and 3.6x EV/EBITDA, you’re getting a lot of asset and earning power for the price. The cumulative free cash flow over the past decade (S$204M) exceeds the current market cap (S$183M). That’s the kind of number that makes value investors pay attention.

This is a stock that doesn’t show up on most screens. It’s too small for institutions, too boring for retail momentum chasers, and too niche for thematic funds. Sometimes that’s exactly where the opportunities are.

All financial data extracted directly from publicly available annual reports filed with SGX. Market data from public financial data providers as of April 2026..

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Tiong Woon Corporation Holding Ltd’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

If that’s true, Kimly Limited might be one of the best businesses in Singapore. The company operates traditional coffee shops across the island’s heartland estates - the kind of neighbourhood kopitiam where aunties and uncles queue for S$3 mixed vegetable rice at 6am and zi char dinners come in at under S$10 a head. It’s not sexy. It’s not tech. But it throws off cash like a vending machine.

The stock currently trades at roughly S$0.39, giving it a market capitalisation of around S$486 million. It pays a 5.1% dividend yield, generates over S$85 million in annual operating cash flow, and has compounded earnings at a respectable clip since its 2017 IPO. And yet, at ~14.5x trailing earnings, it’s not priced like a compounder.

So the question is: what are you actually paying for, and is it enough?

The Origin Story: From Hawker Heritage to SGX Listing

Kimly’s story begins in the early 1990s, when founder Lim Hee Liat started managing traditional coffee shops in Singapore’s heartland HDB estates. The name “Kimly”, rendered in Chinese as 金味 (jin wei, meaning “golden flavour”), reflects the company’s roots in Singapore’s hawker and kopitiam culture, a culinary tradition so distinctive that it earned UNESCO Intangible Cultural Heritage status in 2020. [1]

For over two decades before its IPO, Kimly quietly built what would become one of the largest kopitiam networks on the island. The model was deceptively simple: lease coffee shop premises (typically from HDB), fit them out, recruit and manage food stall tenants, and operate in-house stalls selling staples like dim sum, mixed vegetable rice, and seafood zi char. By the time of its 2018 annual report, the company described itself as having “more than 25 years of experience” in the trade. [2]

The company listed on the Catalist board of the SGX-ST on 20 March 2017, raising net proceeds of S$43.5 million in its IPO. [3] At that point, Kimly operated 67 food outlets and 129 food stalls across the island, with approximately 40% of stalls open 24 hours. [2]

The IPO proceeds were earmarked for outlet expansion, central kitchen upgrades, and working capital - a disciplined deployment that, as of FY2025, has been substantially completed with S$42.8 million utilised out of S$43.5 million raised. [4]

Two pivotal moves reshaped the company after listing. In July 2018, Kimly acquired the Tonkichi and Rive Gauche businesses from Sapporo Lion, adding Japanese dining and confectionery to its portfolio. [2]

Then, in a far more consequential deal, the company acquired Tenderfresh Group in 2021, gaining a halal-certified central kitchen and a network of quick-service restaurants that opened up the Muslim dining market, roughly 15% of Singapore’s population and a fast-growing regional opportunity. [5]

By FY2025, the network had expanded to 84 food outlets, 5 halal food outlets, 142 food stalls and restaurants, and 53 halal food stalls, restaurants, and kiosks, with an occupancy rate of 97.5% across 638 managed stalls. [4]

In FY2025, the company accelerated a shift from pure operator to landlord-operator, acquiring freehold and leasehold properties to secure strategic long-term locations. While a small property rental division had existed since FY2021, the capital deployment escalated dramatically in FY2025 with S$24.1 million in acquisitions.

The Business: Three Pillars, One Ecosystem

Kimly isn’t just a coffee shop operator. It runs a vertically integrated F&B ecosystem built on three complementary divisions.

Outlet Management (40.8% of FY2025 revenue, S$131.7M) is the engine room. Kimly leases coffee shop premises from HDB or private landlords, fits them out, then sub-leases individual stalls to food hawkers. Think of it as a platform business: Kimly provides the location, infrastructure, cleaning, and management; tenants bring their food and pay rent. As of FY2025, the Group manages 68 traditional coffee shops, four industrial canteens, five Halal outlets under the Kedai Kopi brand, and two food courts. The occupancy rate across 638 stalls sits at 97.5%.

Food Retail (56.8% of revenue, S$182.8M) is where Kimly operates its own food stalls. The portfolio is impressively diverse: 49 Dim Sum stalls, 60 Mixed Vegetable Rice stalls, 28 Zi Char stalls, 3 Teochew Porridge stalls, 2 Tonkichi Japanese restaurants, and the entire Tenderfresh halal food operation (53 outlets). Supporting everything is a central kitchen network that supplies sauces, marinades, and semi-finished products.

Outlet Investment (2.4% of revenue, S$7.7M) is the strategic ace. Kimly buys freehold or long-term leasehold coffee shop properties outright. This eliminates lease renewal risk, locks in prime locations permanently, and generates steady rental yields. In FY2025, Kimly acquired two coffee shop properties for S$24.1 million (excluding prior-year prepayments), with a third acquired shortly after the balance sheet date, and this strategy is accelerating.

Signal from the data: Food Retail revenue actually declined from S$185.0M to S$182.8M in FY2025, even as total revenue grew 0.9%. Growth came entirely from Outlet Management (+S$4.5M) and Outlet Investment (+S$0.4M). For a segment that makes up 57% of revenue, this is worth watching closely.

These three divisions create a self-reinforcing flywheel. The outlet management platform generates traffic and tenant demand. The food retail stalls anchor the outlets with popular, consistent food. And the property acquisitions secure the best locations for the long term. The geographic exposure is entirely Singapore: 89 food outlets (84 under the Kimly/foodclique brands plus 5 halal Kedai Kopi outlets) distributed across the island's heartland estates, with 57 operating 24 hours daily.

The Numbers: Boring in the Best Way

Kimly has grown revenue from S$202M in FY2018 to S$322M in FY2025, a CAGR of roughly 6.9%. But the honest story is that most of the growth came in one leap: the Tenderfresh acquisition in 2021, which pushed FY2022 revenue from S$239M to S$318M overnight. Since then, growth has been pedestrian at 1-2% annually. This is a mature, Singapore-only business. You’re not buying a growth stock.

* Excluding S$2.5M gain on disposal of Confectionery Business. ^ Excluding S$1.6M corporate income tax rebate. Net Profit figures represent Group Profit after Tax. EPS is calculated on net profit attributable to owners of the Company.

The FY2021 margins were anomalously high, likely reflecting pandemic-era government support measures and cost relief, though the annual report does not break out the exact impact. The normalised picture since FY2022 shows gross margins stabilising in the 28-29% range, with FY2025 ticking up slightly to 29.2%. EBITDA margins sit at 15-16%, and net margins hover around 11%. Margins have held up well despite relentless cost pressures from manpower, raw materials, and utilities.

ROE has trended downward from a peak of 29.5% in FY2021 to 17.3% in FY2025. This looks concerning in isolation, but it's primarily a function of the equity base growing from S$133M (FY2021) to S$192M (FY2025) through retained earnings and the Tenderfresh acquisition. A 17% ROE still comfortably exceeds any reasonable cost of equity for a consumer F&B business.

Where the Cash Goes

This is where Kimly shines - and where the FY2025 story gets interesting. Operating cash flow of S$85.3M on S$322M revenue is a 26.5% cash conversion rate. But the Group deployed over S$30 million on property acquisitions (including capitalised amounts from prior-year prepayments), S$11.4M repaying bank loans, and S$24.9M on dividends. Cash dropped from S$98.5M to S$68.1M. The balance sheet remains healthy (S$192M equity, no net debt beyond lease liabilities), but the aggressive property spending bears watching - it can’t continue at this pace indefinitely without either slowing down or re-levering.

Total dividends have grown from 0.96 cents per share in FY2018 to 2.00 cents in FY2025, with a payout ratio of approximately 75%. At S$0.39, that’s a 5.1% yield: well-covered by free cash flow even in a heavy investment year. The Board has demonstrated a clear commitment to consistent shareholder returns.

The Moat: Wider Than You’d Think

Traditional coffee shops don’t scream “competitive advantage.” But Kimly has built a quietly formidable position through several reinforcing factors.

HIGH DURABILITY: Scale and Network Density. With 89 food outlets and 195 food stalls, Kimly is one of the largest operators in Singapore. This scale provides procurement leverage, brand visibility, and operational efficiencies. Building a comparable network from scratch would take decades.

HIGH DURABILITY: Central Kitchen Infrastructure. The central kitchens supply sauces, marinades, and semi-finished food products across the network, ensuring consistency, reducing per-unit costs, and easing manpower constraints. This infrastructure took years to develop and is difficult to replicate.

MODERATE (IF EXECUTED WELL): Property Ownership Strategy (Early Stage).Owning coffee shop properties would theoretically eliminate lease renewal risk, but this strategy is unproven at Kimly. In FY2025, the company deployed S$24.1 million to acquire Block 204 Serangoon Central and 110 Yishun Ring Road, with a third property (12 Haig Road) acquired post-balance sheet. The durability of this strategy depends on: (i) actual returns on these properties exceeding the cost of capital, (ii) management’s ability to sustain capex without impairing dividends, and (iii) avoidance of overpaying for real estate. Returns data are not yet disclosed. [6]

MODERATE-HIGH: Tenant Loyalty. Decades of reliable management have built trust with food stall tenants. A 97.5% occupancy rate [4] across 638 stalls reflects this. However, the dip from the historical 98%+ benchmark warrants attention.

Worth watching: After years of high occupancy (98%+ per the FY2018 report), the rate dipped to 97.5% in FY2025. That's roughly 10 fewer occupied stalls. Management attributes this to tenant turnover and outlet renovations. If it stabilises or recovers, it's noise. If it trends toward 95%, it signals structural weakening.

MODERATE: Halal Credentials via Tenderfresh. The 2021 acquisition positioned Kimly in the growing Singapore halal market, with a certified Halal central kitchen and 53 outlets. A notable innovation is the “shared kitchen” concept at two Kedai Kopi locations, housing three Tenderfresh brands (380 Nasi Lemak, Pasta Pizza, Tenderbest) under one roof. This optimises kitchen space, reduces staffing needs, and gives customers multiple options at a single outlet. If replicable across more locations, this model could be meaningful.

Overall moat assessment: moderate to wide within Singapore’s traditional coffee shop industry, with the caveat that it’s geographically bounded to a city-state of 5.9 million people.

Growth Drivers and Headwinds

What Could Drive Upside

Network expansion of 3-5 new outlets annually continues. Recent additions include Blk 302 Ubi Avenue 1 (October 2024) and Block 727 Clementi West (July 2025), plus a joint venture at Block 206 Toa Payoh North. Based on the FY2025 Financial Review, 24 new food stalls collectively contributed approximately S$10.9 million in revenue, though per-outlet economics vary widely by location and format.

Halal segment growth is the biggest lever, but needs to prove itself. The Nasi Kari range sold over 20,000 portions since its May 2025 launch. Hawkerman partnered with Chef Eric Low to launch six regional halal dishes. Tenderfresh was invited to host an immersion visit for international delegates at the Singapore Halal International Seminar 2025. These are promising signals, but management’s own description of halal performance as “stable” rather than “growing” tempers expectations.

Property acquisitions represent a strategic shift beginning in FY2025, with S$24.1 million deployed to acquire Block 204 Serangoon Central and 110 Yishun Ring Road. The company’s rationale is to de-risk locations through ownership rather than lease agreements. However, the financial returns on these acquisitions (cap rate, internal rate of return) are not disclosed, and the company has not guided on the pace or scale of future property purchases. This unproven strategy bears close monitoring.

Operational efficiency gains from rotary ovens, self-service ordering kiosks, shared kitchen concepts [4], and central kitchen automation are designed to offset the industry’s structural manpower shortage.

What Could Go Wrong

HIGH RISK: Manpower. Singapore’s tight labour market and restrictive foreign worker policies make F&B hiring exceptionally difficult. Wage inflation is structural and ongoing.

HIGH RISK: Cost pressures. Food ingredients, utilities, and rentals continue rising. Kimly’s positioning as an affordable dining option limits pricing power.

MODERATE RISK: Geographic concentration. Kimly is 100% Singapore. A severe local downturn or policy change would impact the entire business with no offset.

MODERATE RISK: Management transition at Tenderfresh. Changes in Tenderfresh’s senior leadership, with Mr. Chee Kok Chew Gabriel appointed as Executive Officer to oversee the Tenderfresh Group (per the FY2025 annual report, p.8), introduce execution uncertainty around the halal expansion thesis.

Management and Capital Allocation

Kimly’s Board is chaired by Mr. Lau Chin Huat, a Non-Executive Independent Chairman with over 40 years in audit and advisory. The operational team includes veteran managers with 10+ years at the Group. Founder Lim Hee Liat and his concert parties hold approximately 39.9% of shares [8], with total insider ownership around 66-68% [8]. There is no evidence of recent insider selling.

The capital allocation scorecard is solid. IPO proceeds of S$43.5M have been substantially deployed (S$42.8M utilised) [4]. The Tenderfresh acquisition was transformative. Property purchases are strategically sound and funded internally. Four bank loans totalling S$11.4M were fully repaid in FY2025 [6]. And 74-75% of net profit is returned to shareholders through dividends. One latent observation: with 68% insider ownership, a cash-rich balance sheet, and the Koufu privatisation precedent (2022) [9], a take-private scenario is not far-fetched.

Valuation: Fair, Not Cheap

At 14.5x trailing P/E, Kimly trades in the middle of its historical 10-18x range. A simplified DCF using 2-3% revenue growth, 15.5-16% EBITDA margins, and an 8-9% WACC suggests fair value of S$0.42-0.46. Direct peers are limited since Koufu’s delisting, but against the broader Singapore consumer sector (17-20x P/E), Kimly trades at a discount reflecting its small-cap status and single-country exposure.

The FCF yield of 11.5% stands out. If you view Kimly as a cash flow machine with modest growth optionality, the current price arguably under-appreciates the quality of the cash generation. However, the FY2025 property acquisitions warrant scrutiny: the company deployed S$24.1 million while cash reserves fell by S$30.4 million despite positive operating cash flow, suggesting the landlord strategy is in early stages. The actual cap rate and return on these S$24M+ acquisitions are not disclosed. Investors should monitor whether the property pivot becomes accretive to earnings or merely locks up capital in lower-yielding real estate.

On the other hand, the 1-2% top-line growth caps re-rating potential. Without a catalyst to accelerate growth, the stock is likely to remain range-bound, with total returns driven primarily by dividends.

The Bottom Line

Kimly Limited is a high-quality, boring, cash-generative business trading at a fair but not bargain valuation. The investment thesis is simple: a dominant Singapore kopitiam operator with a durable moat, strong cash generation, a 5.1% dividend yield, and an evolving strategy that’s gradually shifting toward asset ownership.

After reviewing the full trail of SGX filings, the thesis is intact but has nuance. Revenue growth is anaemic (sub-1%). Food Retail, the largest segment, is actually shrinking. The Tenderfresh growth narrative needs more evidence. On the other hand, the property acquisition strategy is adding real, tangible value. The shared kitchen concept [4] is a clever operational innovation. And the massive insider ownership provides alignment and a latent privatisation option.

Bull case: Network expands to 95-100 outlets, Tenderfresh scales via shared kitchens, margins improve through automation. Revenue reaches S$360-380M by FY2028 with net profit of S$40-45M. At 16-18x P/E: S$0.51-0.65 (30-67% upside plus cumulative dividends).

Base case: Steady 1-2% growth, margins hold, dividends maintained at 2.0 cents. At 14-16x P/E: S$0.41-0.51 (5-30% upside plus 5.1% annual yield).

Bear case: Cost pressures compress earnings to S$28-30M, dividend cut to 1.5 cents. At 10-12x P/E: S$0.23-0.29 (25-40% downside).

This is not a multi-bagger candidate. The realistic total return profile is 7-12% annually (5.1% dividend plus 2-7% capital appreciation), which is attractive for a defensive, income-oriented position with a hard asset floor. For value investors who appreciate consistent cash flows, owner-operator mentality, and getting paid to wait, Kimly merits a closer look. The downside is cushioned by tangible assets and a resilient business model. The upside is capped by modest growth but sweetened by yield and optionality.

Revision History

4 May 2026 — Reader corrections incorporated

Two substantive corrections were made following reader comments. Both affect how Kimly’s cash generation should be interpreted, and neither changes the core thesis, but both matter for intellectual honesty.

1. IFRS 16 and true FCF (Cash Flow section)

The original article presented operating cash flow of S$85.3M and FCF of S$56M without flagging the IFRS 16 lease accounting effect. Under IFRS 16, when Kimly signs a new lease the ROU asset and lease liability are recognised simultaneously with no cash changing hands at inception. Lease principal repayments flow through financing cash flows, not operating cash flows, meaning reported OCF is higher than it would be under pre-IFRS 16 treatment where all rent sat as an operating expense.

2. FCF yield overstated (Valuation section)

The original article cited an FCF yield of ~11.5% as a valuation argument. A reader correctly pointed out that this figure does not account for lease principal repayments, which are a real and recurring cash obligation for a lease-heavy operator like Kimly. Once adjusted, the true FCF yield falls to approximately 2–3% in FY2025. The valuation table has been updated accordingly. The underlying investment case that is anchored on dividend sustainability (5.1% yield, well-covered by earnings) and the property acquisition strategy remains unchanged.

References

All factual claims in this article are sourced from the following publicly available documents filed with the Singapore Exchange (SGX) or published by the company:

[1] UNESCO, “Hawker culture in Singapore, community dining and culinary practices in a multicultural urban context,” Intangible Cultural Heritage, inscribed 2020.

[2] Kimly Limited, Annual Report 2018, “Corporate Profile” and “Message to Shareholders,” pp. 1-7.

[3] Kimly Limited, Annual Report 2018, Catalist listing date: 20 March 2017, p. 1.

[4] Kimly Limited, Annual Report 2025, “Corporate Profile,” “Our Businesses,” and “Message to Shareholders,” pp. 1-8.

[5] Kimly Limited, Annual Report 2021 and subsequent reports, Tenderfresh acquisition details.

[6] Kimly Limited, Annual Report 2025, “Financial Review” and “Financial Highlights,” pp. 19-24.

[7] Kimly Limited, Annual Report 2025, “Message to Shareholders — Rewarding Shareholders,” p. 8.

[8] Kimly Limited, SGX filings, substantial shareholder notifications and annual report disclosures (FY2024-FY2025).

[9] “Koufu Group announces privatisation offer at S$0.790 per share,” SGX announcement, 2022.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Kimly Limited’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

Data Sources: Kimly Limited SGX filings, public market data from SGX, Yahoo Finance, and Bloomberg as of April 2026.

On paper, this is a screaming buy. In practice, it’s considerably more complicated.

What HLGE Actually Does Today

Strip away the balance sheet, and HLGE’s operating business is remarkably small. FY2025 revenue was S$6.6 million, virtually all from Copthorne Hotel Cameron Highlands, a 269-room property perched at 1,628 metres in the Malaysian highlands. The hotel earned an operating profit of S$1.5 million. The Group also holds a stalled property development in Melaka, suspended since 1998 in the wake of the Asian Financial Crisis, making it twenty-eight years of inaction, and is reviewing a tender for 48 apartment units in Kea Farm, Cameron Highlands.

Revenue has recovered from COVID lows but remains range-bound at S$5.7–6.7 million. Net profit is modest and entirely dwarfed by the cash balance.

The company does not have a CEO. It does not have an Executive Director. The Executive Committee, chaired by 79-year-old Dato’ Gan Khai Choon, explicitly states it is “not involved in the executive management of the Group’s business.” Day-to-day operations rest with two Key Management Personnel: CFO Foo Yang Hym, who joined in 1984, and hotel General Manager Tee Puat Heng. The entire listed company is run by two people who are not on the board.

This is a lean structure befitting a single-asset company, but it is also one with no strategic mandate, no growth function, and no accountability to minority shareholders for capital allocation.

How a Hotel Became a Cash Box

To understand HLGE, you have to understand its history, because the company you see today bears little resemblance to what it once was.

Founded in 1961 as Lim Kah Ngam (Singapore) Private Limited, the company spent decades building a portfolio of hotel assets across Asia under the Hong Leong Group umbrella. By the mid-2010s, HLGE was a multi-country hospitality operator generating S$13 million in annual revenue, with significant holdings including a 60% stake in Copthorne Hotel Qingdao (a 455-room deluxe hotel in China), interests in Shanghai real estate, and Elite Residences Shanghai (106 serviced apartments). The Group also managed Hotel Equatorial Shanghai, a 506-room property, through a joint venture.

But HLGE was also leveraged. It carried a S$68 million unsecured loan from Venture Lewis Limited, a subsidiary of China Yuchai International, itself a Hong Leong-related entity. The balance sheet was not the fortress it is today.

The transformation came in 2016–2017. Management decided to exit China. The Group listed its Qingdao hotel stake for sale on the Shanghai United Assets and Equity Exchange, and after initial rounds that attracted no bids, eventually completed the disposal in October 2017. One month later, HLGE sold its entire interest in LKNII, the subsidiary holding the Qingdao, Shanghai, and serviced apartment assets. The combined gain: approximately S$86.8 million.

What happened next defined the company’s trajectory for the next decade. Rather than reinvesting in new properties or distributing the windfall to shareholders, management used the proceeds to repay the S$68 million Venture Lewis loan in full. After the repayment, the residual surplus (roughly S$18–19 million) was added to existing cash balances. The company retained only one operating asset: Copthorne Hotel Cameron Highlands.

From that point forward, the cash pile has grown steadily. The hotel generates modest operating cash flow (S$2.1 million in FY2025), capital expenditure is minimal (under S$400,000 annually), and interest income on the deposits adds roughly S$1.5 million per year. No dividends have been paid in at least the past seven financial years. The result: cash balances have climbed from S$55 million in 2018 to S$63.5 million today, a quiet, relentless accumulation with no discernible purpose.

Cash has grown steadily from S$55M to S$63.5M over seven years, consistently exceeding the market capitalisation — yet cumulative dividends paid to shareholders remain at zero.

The Bull Case - And Why It’s Seductive

The value argument is elegantly simple. At S$0.44, you are paying S$41 million for a company holding S$63.5 million in cash, a profitable hotel, and development land. You are buying dollars for roughly 65 cents. The hotel operations come for free, or more precisely, at a negative implied value.

Total equity and cash balances have remained far above the market capitalisation for the entire period. The red-shaded gap between cash and market cap represents the discount investors are paying for every dollar of cash on the balance sheet.

The shareholder register adds to the appeal. According to the company’s FY2024 annual report, the Hong Leong Group, through a chain of entities ultimately linked to Kwek Holdings Pte Ltd and the Kwek family, holds 48.9% of issued shares, while Temasek Holdings has a deemed interest of 12.0% through DBS Group Holdings. These are not speculative punters. The backing of Singapore’s premier property conglomerate and its sovereign wealth fund lends a veneer of credibility. In November 2025, China Yuchai (another Hong Leong entity) purchased 200,000 shares at 33 cents, a purchase totalling just S$66,000, trivial for a company of that size, though it nonetheless triggered a brief run-up to 44 cents.

The bull thesis ultimately rests on catalysts: a privatisation offer from Hong Leong, a special dividend, a share buyback programme, or a meaningful deployment of the cash into value-accretive acquisitions. At the April 2025 AGM, when shareholders pressed management on the cash pile, the board cited three projects in progress — the Kea Farm apartments, the conversion of an entertainment complex into hotel rooms, and the Melaka development.

The Bear Case - And Why the Discount Persists

Every element of the bull case has a structural counterargument.

The cash is real but inaccessible. Minority shareholders cannot force a dividend, a buyback, or a liquidation. The Hong Leong Group controls the company with 48.9% and has shown no inclination to return capital. The board’s stated dividend policy is to “conserve cash for operations and future investment opportunities”, a formulation it has repeated, verbatim, for years. The market isn’t mispricing the cash; it’s correctly pricing the probability that minority shareholders will never see it.

The prestigious register is the problem, not the solution. Hong Leong’s controlling stake is what creates the value trap. They already control the company and its cash. A privatisation under the Singapore Code on Take-overs would require a premium to the prevailing market price and an independent financial adviser would likely benchmark any offer against NAV. At NAV of S$0.88 per share, buying out the 51% Hong Leong doesn’t own would cost roughly S$42 million, not the S$21 million a naive calculation at market price would suggest. Why would they spend that when the status quo already serves them? Temasek’s 12% is likely a legacy holding through DBS, too small for active management. Neither shareholder has any incentive to act as an activist catalyst.

The projects are recycled talking points. The Melaka development has been suspended since the 1998 Asian Financial Crisis. The entertainment complex conversion has been awaiting regulatory approval for years. The Kea Farm tender is being reviewed with a focus on cost reduction, suggesting the economics may not work. These are not catalysts, they are justifications for inaction, trotted out at AGMs to deflect shareholder frustration.

The hotel faces structural headwinds. Cameron Highlands is experiencing an oversupply of hotel apartments and homestays, which management itself has flagged repeatedly. Rising operating costs from Malaysia’s minimum wage increases and skilled labour shortages are compressing margins. The Hotel Equatorial Shanghai licence agreement was terminated in March 2025, eliminating a recurring income stream. CHCH is a decent hotel in a competitive market, but it has limited pricing power and no clear path to meaningful revenue growth.

Compensation absorbs a significant share of profits. Directors’ fees of S$192,000 plus total KMP compensation (employee benefits and employer CPF contributions) of S$335,000 brought total key management compensation to S$527,000 in FY2025, according to the company’s financial statements. That represents 36% of FY2025 net profit of S$1.47 million, for a company that pays nothing to shareholders. There are no performance-linked fees, no share options have ever been granted under the 2006 scheme, and no clawback mechanisms exist. The board is compensated for maintaining the status quo.

A breakdown of FY2025 economics: the hotel and interest income generate nearly S$3 million, but corporate overhead, property development losses, directors’ fees, and management compensation consume a significant portion, while shareholders receive nothing.

The Verdict: Deep Value With an Indefinite Holding Period

The share price has traded at a persistent 50–65% discount to NAV for over seven years. Even cash per share alone has consistently exceeded the stock price. The recent narrowing from a 65% discount to 50% is notable but the gap remains wide.

HLGE is not a fraud. It is not a poorly run company in the conventional sense, the hotel is maintained, the accounts are clean (audited by Ernst & Young), and the balance sheet is pristine. It is simply a company where the interests of the controlling shareholder and minority shareholders have diverged, and there is no mechanism to realign them.

The downside is well-protected. It is difficult to envision a scenario where you permanently lose capital at S$0.44 when the company holds S$0.676 per share in cash and generates positive operating cash flow. But capital protection is not the same as capital appreciation. Without a catalyst, you are buying a stock that pays no yield, offers minimal liquidity (many days see fewer than 200 shares traded), and depends entirely on the goodwill of a controlling shareholder for value realisation.

The recent price action, from roughly S$0.25 a year ago to S$0.44 today, a 76% gain, suggests some investors are beginning to pay attention. The China Yuchai share purchase and The Edge Singapore’s coverage have brought new eyes to the name. But attention alone doesn’t unlock value. What would change the thesis is a concrete action: a dividend policy, a buyback mandate, a privatisation offer, or a genuinely transformative acquisition. None of these appear imminent.

For patient, deep-value investors with a multi-year horizon and high tolerance for illiquidity, HLGE offers an asymmetric risk-reward: limited downside, potentially significant upside, but with no visibility on timing. For everyone else, it remains a fascinating case study in how a company can be simultaneously cheap on every metric and yet offer no clear path to value realisation.

The S$63.5 million sits in the bank. The question, as it has been for years, is whether it will ever find its way to shareholders.

References

All factual claims in this article are sourced from the following publicly available documents filed with the Singapore Exchange (SGX) or published by the company:

[1] HL Global Enterprises Limited, Full Year Financial Statements and Related Announcement for FY2025 (Broadcast: 13 Feb 2026). — Revenue of S$6,551k (p.1); cash & bank deposits of S$63,481k (p.2); net cash from operations S$2,071k (p.4); capex S$303k (p.6); interest income S$1,499k, Note 6 (p.9); directors’ fees S$192k, Note 7 (p.9); KMP employee benefits S$313k and CPF S$22k, Note 8 (p.9); Melaka development suspended since 1998, Note 12 (p.12); no share options granted under SOS 2006, Note 14 (p.13).

[2] HL Global Enterprises Limited, Annual Report 2025 (FY ended 31 Dec 2025). — Hotel description: 269 guestrooms, 1,628 metres elevation (p.8); Dato’ Gan Khai Choon, age 79, Chairman Non-Executive (p.4); Ms Foo Yang Hym joined 1984 (p.7); Executive Committee not involved in executive management (p.1); Ernst & Young LLP as auditor (p.1); Hotel Equatorial Shanghai licence terminated effective 1 March 2025 (p.2); hospitality segment operating profit S$1.5 million (p.2); Kea Farm 48 apartment units, reviewing tender with aim to reduce development costs (p.3); entertainment complex conversion pending regulatory approval (p.3); no dividend recommended, cash conserved for operations and future investment (p.2).

[3] HL Global Enterprises Limited, Annual Report 2024 (FY ended 31 Dec 2024). — Substantial shareholders: Grace Star Services (48.90% direct), chain of deemed interests through Hong Leong entities to Kwek Holdings Pte Ltd; Temasek Holdings 11.98% deemed interest through DBS Group Holdings (Analysis of Shareholdings section); issued shares 93,915,337 excl. 2,418,917 trust shares.

[4] HL Global Enterprises Limited, Annual Report 2017. — Gain of S$86.8 million from the LKNII and Qingdao disposals (Chairman’s Statement); completion of CHQ disposal Oct 2017 and LKNII disposal Nov 2017.

[5] HL Global Enterprises Limited, Annual Report 2015. — S$68 million unsecured loan from Venture Lewis Limited (Chairman’s Statement, p.5); Copthorne Hotel Qingdao 60% stake, 455 guestrooms (p.2); Elite Residences Shanghai 106 apartment units (p.2); Hotel Equatorial Shanghai 506 guest rooms (p.3).

[6] HL Global Enterprises Limited, Annual Report 2018. — Repayment of S$68 million Venture Lewis loan from disposal proceeds; founding as Lim Kah Ngam (Singapore) Private Limited in 1961.

[7] “Our 2026 Picks: HL Global Enterprises — Undervalued Despite Big Names”, The Edge Singapore (Dec 2025). — China Yuchai purchase of 200,000 shares at 33 cents average in November 2025.

[8] SGinvestors.io, HL Global Enterprises Share Price History (SGX:AVX), accessed April 2026. — Historical share price data; S$0.44 as of 2 April 2026; approximately S$0.25 level in April–May 2025.

[9] HL Global Enterprises Limited, Annual Reports FY2019–FY2024 (SGX filings). — Historical revenue, net profit, cash balances, total equity, and NAV per share data used in charts and trend analysis across all seven fiscal years.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from HL Global Enterprises’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

Data Sources: HL Global Enterprises SGX filings, public market data from SGX, Yahoo Finance, and Bloomberg as of April 2026.

If you’ve ever used Tiger Balm, you’ve used a Haw Par product. But here’s what most people don’t realise: Tiger Balm is only the third-most important thing about this company.

Haw Par Corporation (SGX: H02) is a Singapore-listed conglomerate that owns the globally recognised Tiger Balm brand, sold in over 100 countries. [1] But beneath the familiar red-and-gold packaging sits a S$3.4 billion strategic investment portfolio, primarily stakes in United Overseas Bank (UOB) and UOL Group, plus S$791 million in cash. The healthcare business, while iconic, contributed just 24% of FY2025 group profit.

This piece walks through the numbers, the structure, and the key questions investors should be thinking about.

Snapshot

Three Businesses, One Stock

Haw Par reports three segments, and understanding their relative weight is crucial to understanding the stock.

1. Healthcare (Tiger Balm & Kwan Loong [8]): The consumer-facing brand. FY2025 revenue of S$210 million across over 100 countries, [1] with segment profit of S$67 million and margins of ~32%. This is the business most people think of when they hear “Haw Par.”

2. Investments: The real engine. Haw Par holds ~74.8 million UOB shares (worth S$2.6 billion) and ~72 million UOL shares (worth S$628 million) [2], plus S$139 million in other investments. In FY2025, this segment generated S$205 million in profit, three times the healthcare business, primarily through S$189 million in dividend income.

3. Property & Leisure: A smaller segment contributing S$19.6 million in revenue (mostly rental income) and S$10.6 million in profit from industrial and commercial properties.

Financial Performance: Recovering Healthcare, Surging Investment Income

Over the past nine years, Haw Par’s story has been one of recovering healthcare revenue — which fell sharply during COVID (FY2020 revenue was just S$111 million) before rebounding strongly — paired with accelerating investment income. Healthcare revenue has grown at a modest ~2.0% CAGR over the period, but net profit has compounded at ~8.7% annually, driven almost entirely by rising dividend payouts from UOB.

Gross margins have recovered strongly from the COVID-era low of 44% in FY2020, stabilising in the 54–58% range since FY2022, reflecting Tiger Balm’s pricing power. The balance sheet is a fortress: S$791 million cash, S$44 million debt (debt-to-equity of just 1%), and S$4.29 billion in total equity.

The Dividend Story: A Regime Change?

For years, Haw Par paid a predictable 30 cents per share annually (15 cents interim + 15 cents final). That started to shift in FY2023 with a bump to 35 cents, then 40 cents in FY2024, and FY2025 brought a S$1.00 special dividend on top — bringing total payout to S$1.40 per share, a 250% increase year-on-year.

Where does the dividend money come from?

UOB dividends to Haw Par: ~S$135 million (estimated based on 74.8m shares × S$1.80 regular DPS) [3]

Total investment dividends received: S$189 million

Total dividends Haw Par paid out: S$310 million

UOB alone funds ~44% of the total payout and ~72% of all investment dividend income.

The regular 40-cent dividend is well-covered by UOB income alone. But the S$1.00 special dividend required tapping cash reserves. Whether this becomes a recurring feature is one of the biggest questions for the stock.

Geographic Revenue Mix

Nearly 30% of revenue now comes from outside Asia, signalling that Tiger Balm’s push into Western markets is gaining traction. The global wellness and natural remedy trend is a meaningful tailwind for the brand.

Sum-of-the-Parts: What Are You Actually Buying?

Given Haw Par’s hybrid nature, a sum-of-the-parts approach is the most useful valuation lens.

At S$16.80, the stock trades roughly in line with the discount-adjusted SOTP of ~S$17.11 — suggesting the recent rally has captured most of the obvious valuation gap. Gross SOTP of S$22.81 implies 36% upside, but the 25% holding company discount (standard for Singapore conglomerates) narrows that considerably.

What Could Go Right

Sustained special dividends — If management commits to returning excess capital regularly, the stock could re-rate as an income vehicle. A sustainable S$1.00+ annual payout would imply a yield of approximately 6%.

Tiger Balm’s international expansion — Western market penetration remains low. Successfully growing the “rest of world” segment at 8–10% annually could lift overall healthcare revenue growth meaningfully.

NAV accretion — If UOB and UOL share prices continue to appreciate, Haw Par’s NAV grows automatically, and dividend income rises in tandem.

Corporate restructuring — Minority shareholder activism at UOI (part of the Wee family holding structure) has pushed for Haw Par share distributions, [7] which could be a catalyst for value-unlocking actions.

What Could Go Wrong

⚠️ Concentration risk: UOB alone represents 59% of Haw Par’s total assets. A significant decline in UOB’s share price or a dividend cut would materially impact NAV and income.

Healthcare stagnation — Tiger Balm revenue declined 6.9% in FY2025. If the brand fails to connect with younger consumers or competition intensifies, the healthcare business could be a drag.

Dividend reversal — The special dividend is not guaranteed. If the company reverts to a regular 40-cent payout without specials, the yield drops to ~2.4% and the income thesis weakens.

Holding company discount persists — The gap between gross SOTP (S$22.81) and market price may never fully close without a structural catalyst. Patient capital is required.

Haw Par vs Buying UOB Directly

A fair question many investors ask: why not just buy UOB? Here’s how the numbers compare.

UOB direct is simpler, more liquid, and offers a cleaner yield. Haw Par offers discounted access to a basket of Singapore blue-chip assets plus a globally recognised consumer brand — but with conglomerate complexity and a structural discount. They suit different investor profiles.

Key Metrics at a Glance

Bottom Line

Haw Par is a unique asset in the SGX universe — part heritage consumer brand, part blue-chip investment vehicle, part cash fortress. The stock offers genuine downside protection (fortress balance sheet, low beta, NAV floor), attractive income potential (if special dividends recur), and a globally recognised brand with international growth runway.

The recent rally from S$11.30 to S$16.80 has captured much of the easy upside, but total return potential remains reasonable for patient, income-oriented investors. The key catalysts to watch are dividend policy evolution, Tiger Balm’s Western market traction, and any corporate restructuring signals from the Wee family holding structure.

Whether this stock suits your portfolio depends on your investment horizon, income needs, and comfort with conglomerate structures. As always, do your own homework before making any investment decisions.

Notes & Sources

1. Tiger Balm sold in over 100 countries — Per Haw Par Corporation’s corporate website (hawpar.com/healthcare) and the Tiger Balm brand page. Also referenced in the Wikipedia article on Tiger Balm.

2. Share counts: ~74.8 million UOB shares & ~72 million UOL shares — Exact figures (74,850,539 UOB ordinary shares and 72,044,768 UOL ordinary shares) are disclosed in the Haw Par Corporation Annual Report 2024, available at investor.hawpar.com. Also confirmed in the FY2025 full-year SGX filing.

3. UOB FY2024 regular DPS of S$1.80 — Per UOB’s FY2024 results announcement via UOB Investor Relations. UOB declared a total ordinary dividend of S$1.80 per share for FY2024 (85 cents interim + 95 cents final). Also reported by The Edge Singapore.

4. Beta of 0.22 — Sourced from Stock Analysis (SGX: H02), based on 5-year monthly returns vs. the Straits Times Index. Beta values may vary by provider and calculation methodology.

5. 52-week range (S$11.30 – S$17.33) and share price (S$16.80) — Market data sourced from Yahoo Finance (H02.SI) and SGX market data as of early April 2026.

6. Asia Pharma Average comparisons — Industry average multiples (P/E 22.1x, P/B 1.5–2.0x, etc.) are approximate figures derived from Aswath Damodaran’s sector-level data (pages.stern.nyu.edu/~adamodar) and Bloomberg industry composites for Asia-Pacific healthcare/pharmaceutical companies. These are indicative ranges rather than a single authoritative benchmark.

7. UOI minority shareholder activism — Reported by The Edge Singapore in multiple articles through 2024–2025, covering minority shareholders’ push for United Overseas Insurance (UOI) to distribute its Haw Par shares. Also discussed on Minichart.com.sg (March 2025).

8. Kwan Loong as a Haw Par brand — Kwan Loong is manufactured by Haw Par Healthcare and registered with the U.S. FDA (listed on Drugs.com). Also confirmed on Haw Par Corporation’s corporate website (hawpar.com).

9. EV/EBITDA estimate of ~10x — Author’s estimate. Haw Par does not report EBITDA directly in its SGX filings. This figure is derived by estimating EBITDA from reported operating profit plus depreciation/amortisation, against an enterprise value calculated from market capitalisation plus debt minus cash. Readers should treat this as an approximation.

IMPORTANT DISCLAIMERS

General Disclaimer: This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The views expressed are based on publicly available data from Haw Par Corporation’s SGX filings and publicly accessible market data, and may not reflect the most current developments.

Not Licensed Financial Advice: The author is not a licensed financial adviser, and this publication is not issued by a holder of a Capital Markets Services Licence under the Securities and Futures Act 2001 of Singapore. This content does not fall within the definition of “financial advisory service” under the Financial Advisers Act 2001 of Singapore. Readers in Singapore should note that this content is exempt from the requirements of the Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication.

MAS Compliance Notice: In accordance with the Monetary Authority of Singapore’s guidelines, this publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, you should consult a licensed financial adviser who can provide advice tailored to your personal circumstances. Past performance of any security discussed herein is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

Data Sources: Haw Par Corporation SGX filings (FY2016–FY2025), public market data from SGX, Yahoo Finance, and Bloomberg as of April 2026.